<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2025-06-24T04:16:37Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10821037" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:10821037</identifier><datestamp>2024-01-28</datestamp><setSpec>vaccines</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.3/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="accession">PMC10821037</article-id><article-id pub-id-type="pmcid">PMC10821037</article-id><article-id pub-id-type="pmc-uid">10821037</article-id><article-id pub-id-type="pmid">38250885</article-id><article-id pub-id-type="pmid">38250885</article-id>
<article-id pub-id-type="doi">10.3390/vaccines12010072</article-id><article-id pub-id-type="publisher-id">vaccines-12-00072</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Differences in the Evolution of Clinical, Biochemical, and Hematological Indicators in Hospitalized Patients with COVID-19 According to Their Vaccination Scheme: A Cohort Study in One of the World’s Highest Hospital Mortality Populations</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7646-0842</contrib-id><name><surname>Mendoza-Hernandez</surname><given-names>Martha A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vaccines-12-00072" ref-type="aff">1</xref><xref rid="af2-vaccines-12-00072" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6727-0051</contrib-id><name><surname>Guzman-Esquivel</surname><given-names>Jose</given-names></name><xref rid="af3-vaccines-12-00072" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Ramos-Rojas</surname><given-names>Marco A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref rid="af2-vaccines-12-00072" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Santillan-Luna</surname><given-names>Vanessa V.</given-names></name><xref rid="af1-vaccines-12-00072" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Sanchez-Ramirez</surname><given-names>Carmen A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref rid="af1-vaccines-12-00072" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4685-3095</contrib-id><name><surname>Hernandez-Fuentes</surname><given-names>Gustavo A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref rid="af1-vaccines-12-00072" ref-type="aff">1</xref><xref rid="af4-vaccines-12-00072" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Diaz-Martinez</surname><given-names>Janet</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><xref rid="af5-vaccines-12-00072" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Melnikov</surname><given-names>Valery</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref rid="af1-vaccines-12-00072" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1744-9173</contrib-id><name><surname>Rojas-Larios</surname><given-names>Fabian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref rid="af1-vaccines-12-00072" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1478-9068</contrib-id><name><surname>Martinez-Fierro</surname><given-names>Margarita L.</given-names></name><xref rid="af6-vaccines-12-00072" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Tiburcio-Jimenez</surname><given-names>Daniel</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref rid="af1-vaccines-12-00072" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5988-4168</contrib-id><name><surname>Rodriguez-Sanchez</surname><given-names>Iram P.</given-names></name><xref rid="af7-vaccines-12-00072" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Delgado-Enciso</surname><given-names>Osiris G.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref rid="af1-vaccines-12-00072" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Cabrera-Licona</surname><given-names>Ariana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref rid="af4-vaccines-12-00072" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9848-862X</contrib-id><name><surname>Delgado-Enciso</surname><given-names>Ivan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref rid="af1-vaccines-12-00072" ref-type="aff">1</xref><xref rid="af4-vaccines-12-00072" ref-type="aff">4</xref><xref rid="af8-vaccines-12-00072" ref-type="aff">8</xref><xref rid="c1-vaccines-12-00072" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Ye</surname><given-names>Qing</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-00072"><label>1</label>School of Medicine, University of Colima, Colima 28040, Mexico; <email>mendoza_martha@ucol.mx</email> (M.A.M.-H.); <email>vvsantillanluna@gmail.com</email> (V.V.S.-L.); <email>carmen_sanchez@ucol.mx</email> (C.A.S.-R.); <email>gahfuentes@gmail.com</email> (G.A.H.-F.); <email>valery.melnikoff@gmail.com</email> (V.M.); <email>frojas@ucol.mx</email> (F.R.-L.); <email>leinad_dicapriano@hotmail.com</email> (D.T.-J.); <email>1933osiris@gmail.com</email> (O.G.D.-E.)</aff><aff id="af2-vaccines-12-00072"><label>2</label>General Hospital of Zone 1, Colima Delegation, Mexican Institute of Social Security, Villa de Álvarez, Colima 28984, Mexico; <email>marcoz74@hotmail.com</email></aff><aff id="af3-vaccines-12-00072"><label>3</label>Clinical Epidemiology Research Unit, Mexican Institute of Social Security, Villa de Alvarez, Colima 28984, Mexico; <email>pepeguzman_esquivel@outlook.com</email></aff><aff id="af4-vaccines-12-00072"><label>4</label>Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico; <email>arianacabrera267@gmail.com</email></aff><aff id="af5-vaccines-12-00072"><label>5</label>Research Center in Minority Institutions, Robert Stempel College of Public Health, Florida International University, Miami, FL 33199, USA; <email>jdiaz@caridad.org</email></aff><aff id="af6-vaccines-12-00072"><label>6</label>Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, Mexico; <email>margaritamf@uaz.edu.mx</email></aff><aff id="af7-vaccines-12-00072"><label>7</label>Molecular and Structural Physiology Laboratory, School of Biological Sciences, Autonomous University of Nuevo Leon, San Nicolas de los Garza 66455, Mexico; <email>iramrodriguez@gmail.com</email></aff><aff id="af8-vaccines-12-00072"><label>8</label>Department of Dietetics and Nutrition, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL 33199, USA</aff><author-notes><corresp id="c1-vaccines-12-00072"><label>*</label>Correspondence: <email>ivan_delgado_enciso@ucol.mx</email> or <email>ivadelga@fiu.edu</email>; Tel.: +52-312-3161099</corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>1</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2024</year></pub-date><volume>12</volume><issue>1</issue><elocation-id>72</elocation-id><history><date date-type="received"><day>30</day><month>11</month><year>2023</year></date><date date-type="rev-recd"><day>27</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>29</day><month>12</month><year>2023</year></date></history><permissions><copyright-statement>© 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>COVID-19 vaccines primarily prevent severe illnesses or hospitalization, but there is limited data on their impact during hospitalization for seriously ill patients. In a Mexican cohort with high COVID-19 mortality, a study assessed vaccination’s effects. From 2021 to 2022, 462 patients with 4455 hospital days were analyzed. The generalized multivariate linear mixed model (GENLINMIXED) with binary logistic regression link, survival analysis and ROC curves were used to identify risk factors for death. The results showed that the vaccinated individuals were almost half as likely to die (adRR = 0.54, 95% CI = 0.30–0.97, <italic toggle="yes">p</italic> = 0.041). When stratifying by vaccine, the Pfizer group (BNT162b2) had a 2.4-times lower risk of death (adRR = 0.41, 95% CI = 0.2–0.8, <italic toggle="yes">p</italic> = 0.008), while the AstraZeneca group (ChAdOx1-S) group did not significantly differ from the non-vaccinated (adRR = 1.04, 95% CI = 0.5–2.3, <italic toggle="yes">p</italic> = 0.915). The Pfizer group exhibited a higher survival, the unvaccinated showed increasing mortality, and the AstraZeneca group remained intermediate (<italic toggle="yes">p</italic> = 0.003, multigroup log-rank test). Additionally, BNT162b2-vaccinated individuals had lower values for markers, such as ferritin and D-dimer. Biochemical and hematological indicators suggested a protective effect of both types of vaccines, possibly linked to higher lymphocyte counts and lower platelet-to-lymphocyte ratio (PLR). It is imperative to highlight that these results reinforce the efficacy of COVID-19 vaccines. However, further studies are warranted for a comprehensive understanding of these findings.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>hospitalized patients</kwd><kwd>vaccination scheme</kwd><kwd>mortality</kwd><kwd>diagnostic markers</kwd><kwd>cohort study</kwd></kwd-group><funding-group><award-group><funding-source>National Council of Humanities, Sciences and Technologies (CONAHCYT)</funding-source><award-id>319282</award-id></award-group><funding-statement>The present study was supported by the National Council of Humanities, Sciences and Technologies (CONAHCYT) (grant no. 319282; Call for Frontier Science, Modality: Paradigms and Controversies of Science).</funding-statement></funding-group></article-meta></front>
  <body>
    <sec sec-type="intro" id="sec1-vaccines-12-00072">
      <title>1. Introduction</title>
      <p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease (COVID-19), a genuinely multisystemic illness despite its primary impact on the respiratory system [<xref rid="B1-vaccines-12-00072" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-12-00072" ref-type="bibr">2</xref>]. While most infections are self-limiting or necessitate ambulatory care, 20% of symptomatic, unvaccinated adults may require hospitalization [<xref rid="B2-vaccines-12-00072" ref-type="bibr">2</xref>]. Vaccination has been shown to reduce this hospitalization rate by up to 10 times [<xref rid="B3-vaccines-12-00072" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-12-00072" ref-type="bibr">4</xref>]. Regional and country-specific factors can influence the proportion of patients developing severe/critical COVID-19 and requiring hospitalization [<xref rid="B5-vaccines-12-00072" ref-type="bibr">5</xref>].</p>
      <p>During the initial years of the pandemic, various types of COVID-19 vaccines were developed. The most widely distributed include: (1) mRNA-based vaccines such as BNT162b2 (Pfizer—BioNTech) and mRNA-1273 (Moderna—NIAID); (2) adenoviral vector-based vaccines like ChAdOx1-S (Oxford—AstraZeneca), Ad26.COV2.S (Johnson &amp; Johnson), Gam-COVID-Vac (Gamaleya), and Ad5nCoV (CanSino); and (3) inactivated coronavirus-based vaccines like CorovaVac (Sinovac) and BBIBP-CorV (Sinopharm) [<xref rid="B1-vaccines-12-00072" ref-type="bibr">1</xref>,<xref rid="B3-vaccines-12-00072" ref-type="bibr">3</xref>,<xref rid="B6-vaccines-12-00072" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-12-00072" ref-type="bibr">7</xref>]. From a global public health perspective, the primary and extensively studied benefit of vaccines is their efficacy in preventing disease or severe outcomes (reducing hospitalizations), ranging from 70 to 95% [<xref rid="B3-vaccines-12-00072" ref-type="bibr">3</xref>], varying based on the population and the investigated vaccine type [<xref rid="B3-vaccines-12-00072" ref-type="bibr">3</xref>].</p>
      <p>When vaccination fails to prevent hospitalization in vaccinated individuals, an understudied scenario arises, and existing reports contradict whether being vaccinated modifies the mortality of these patients [<xref rid="B7-vaccines-12-00072" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-00072" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-12-00072" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-12-00072" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-12-00072" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-12-00072" ref-type="bibr">12</xref>]. Additionally, how vaccines alter the clinical course and predictors of death in patients with severe/critical COVID-19 remains unknown. This is a pertinent topic that may vary not only with the type of vaccine but also in the context of the analyzed population. Mortality in hospitalized COVID-19 patients worldwide has varied from 1% to 52% [<xref rid="B13-vaccines-12-00072" ref-type="bibr">13</xref>], greatly influenced by the pandemic’s temporality, ethnic and sociocultural characteristics of each population, and the diverse therapeutic strategies applied in different regions [<xref rid="B14-vaccines-12-00072" ref-type="bibr">14</xref>].</p>
      <p>From March 2020 to August 2022, in Mexico, the overall hospital case fatality rate was 45.1% (95% CI 44.9, 45.3), with variations depending on the pandemic period, reaching a maximum peak of 50.8% overall [<xref rid="B6-vaccines-12-00072" ref-type="bibr">6</xref>], including a peak mortality rate of 60% in hospitalized individuals aged 60 or older [<xref rid="B6-vaccines-12-00072" ref-type="bibr">6</xref>]. This places Mexico among the populations with the highest mortality in hospitalized COVID-19 patients globally. In this challenging population context, a cohort study was conducted to understand the effects of administering different types of vaccines on the clinical evolution of hospitalized patients and whether such vaccines induce changes capable of modifying the risk of death.</p>
    </sec>
    <sec id="sec2-vaccines-12-00072">
      <title>2. Materials and Methods</title>
      <sec id="sec2dot1-vaccines-12-00072">
        <title>2.1. Study Subjects</title>
        <p>An ambispective cohort study was conducted with patients admitted to the COVID-19 unit at General Hospital Number 1 of IMSS-Colima, Mexico, experiencing severe or critical COVID-19 between January 2021 and December 2022. Inclusion criteria encompassed men and nonpregnant women, aged ≥ 18, with confirmed severe or critical COVID-19 through positive SARS-CoV-2 RT-PCR or antigen test results. Patients admitted to regular hospital floors, high-flow oxygen rooms, or intensive care units (ICUs) were included, while those solely receiving care in the emergency room without admission were excluded. Subjects lacking information on vaccination status or with incomplete clinical records were eliminated. Considering the above in a cohort of 1747 hospitalized individuals, 514 were included based on predetermined inclusion and exclusion criteria. Notably, 288 of these patients (56.1%) had not received vaccination, while the remaining 226 (43.9%) had been vaccinated (<xref rid="vaccines-12-00072-f001" ref-type="fig">Figure 1</xref>).</p>
        <p>The study received approval from the local health research committee of IMSS-Colima, Mexico (approval number R-2020-601-041, 24 September 2020). As data were obtained from clinical records, and not directly from patients, the ethics committee waived the requirement for signed consent from each subject. Anonymity was ensured, and personal identification was concealed in the collected databases used for analysis.</p>
      </sec>
      <sec id="sec2dot2-vaccines-12-00072">
        <title>2.2. Measures and Follow-Up</title>
        <p>Data were extracted from patients’ clinical records, encompassing personal history, vaccination history against COVID-19, and clinical parameters throughout their hospitalization until discharge, either due to improvement or death. The following variables were universally collected: age, sex, personal history (comorbidities, Charlson comorbidity index score), COVID-19 vaccination history (brand, number of doses, time since last dose), history of previous COVID-19 infections, smoking status (considering only current smokers per the Glossary of the National Health Interview Survey of the United States of America) [<xref rid="B15-vaccines-12-00072" ref-type="bibr">15</xref>], admission disease phase (viral/pulmonary/hyperinflammatory) [<xref rid="B16-vaccines-12-00072" ref-type="bibr">16</xref>], and clinical, laboratory, and imaging data for each day of hospital stay, along with the reason for discharge (death or improvement).</p>
        <p>Repetitively collected data during hospitalization included: blood cell counts (neutrophils, lymphocytes, platelets), inflammation markers (neutrophil/lymphocyte ratio—NLR, Ferritin, Erythrocyte Sedimentation Rate, and C-Reactive Protein Level), glucose, creatinine, liver enzymes (alkaline phosphatase—ALP, aspartate amino transferase—AST, alanine aminotransferase—ALT, and Lactate Dehydrogenase—LDH), prothrombin time expressed as an international normalized ratio (INR), development of acute kidney disease (AKI), use of mechanical ventilation or hemodialysis, administration of medications (paracetamol, anticoagulants, antibiotics, amine support, steroids, and diuretics), and the calculation of risk scores using various clinical parameters such as COVID-GRAM, National Early Warning Score 2 (NEWS-2), and Pneumonia Severity Index (PSI). The estimated glomerular filtration rate (eGFR) was determined from serum creatinine, following the CKD-EPI 2021 equation [<xref rid="B17-vaccines-12-00072" ref-type="bibr">17</xref>]. These data were repeatedly collected throughout the entire hospital stay.</p>
      </sec>
      <sec id="sec2dot3-vaccines-12-00072">
        <title>2.3. Sample Size</title>
        <p>The sample size for this study was determined based on the observation of mortality differences between various groups, akin to effective pharmacological interventions. The calculation was derived from previously reported mortality rates following the use or non-use of corticosteroids (41.3% and 24.8%, respectively) in hospitalized COVID-19 patients requiring high-flow oxygen [<xref rid="B18-vaccines-12-00072" ref-type="bibr">18</xref>]. To achieve the required power of 0.8, 126 patients were needed in each group (vaccinated and unvaccinated). Following the study’s completion, a post hoc statistical power analysis was conducted, revealing that being vaccinated (with two doses of BNT162b2 (Pfizer—BioNTech) or ChAdOx1-S (AstraZeneca) vaccines) reduces mortality in hospitalized COVID-19 patients, resulting in a statistical power of 93.3% for the vaccinated group and 96% for the subgroup vaccinated with BNT162b2.</p>
      </sec>
      <sec id="sec2dot4-vaccines-12-00072">
        <title>2.4. Statistical Analysis</title>
        <p>Data representation utilized percentages and mean ± standard deviation. The normality of data was assessed with Kolmogorov-Smirnov tests. Fisher’s exact tests or likelihood ratio chi-square tests were employed for comparing categorical data among groups. When applicable, independent Student’s t-tests or ANOVA were used to compare numerical data between two or three groups. The values of various clinical characteristics throughout the entire hospitalization period were analyzed for their predictive ability regarding patient death, utilizing the area under the Receiver Operating Characteristic (ROC) curve (AUC), confidence interval, cut-off point, sensitivity, and specificity.</p>
        <p>Association analysis was conducted using multivariate generalized linear mixed models (GLMM, GENLINMIXED in SPSS) with a binary logistic regression link and separate random intercepts (SPRI), as previously described [<xref rid="B19-vaccines-12-00072" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-12-00072" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-12-00072" ref-type="bibr">21</xref>]. Data were summarized as relative risks (RRs) with 95% confidence intervals (CIs) and <italic toggle="yes">p</italic>-values, adjusted for multiple variables. GLMM is a valid strategy for estimating RRs in multivariate analysis [<xref rid="B21-vaccines-12-00072" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-12-00072" ref-type="bibr">22</xref>].</p>
        <p>Two random variables were incorporated to account for the longitudinal nature of the data: (I) day of hospital stay, and (II) month of hospital admission (pandemic time, month 1 January 2021, to month 24 December 2022). The target variable was the patient’s death during hospital stays (dichotomous; yes or no). Fixed effects included continuous variables (Charlson Index) and dichotomous variables indicating various clinical characteristics and vaccine types. Numerical clinical variables were dichotomized based on the cut-off point obtained from ROC curve calculations predicting patient death. Covariance structures were selected based on Akaike’s Information Criterion (AIC). The primary objective of the model was to obtain marginal risk by summarizing binomial regression parameters into relative risk (RR) with 95% confidence intervals (CI) and <italic toggle="yes">p</italic>-values. Univariate linear mixed effects model tests were used to compare the evolution of clinical parameters between different vaccine groups (fixed effects) during the hospitalization period (repeated observations), employing the two random variables described earlier ). Statistical power and sample size were calculated using CinCalc version 1 (<uri xlink:href="https://clincalc.com/stats/Power.aspx">https://clincalc.com/stats/Power.aspx</uri> (16 September 2023)) [<xref rid="B21-vaccines-12-00072" ref-type="bibr">21</xref>]. All other analyses were performed using SPSS Statistics version 20 software (IBM Corp., Armonk, NY, USA). A significance level of <italic toggle="yes">p</italic> &lt; 0.05 was considered statistically significant.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="sec3-vaccines-12-00072">
      <title>3. Results</title>
      <sec id="sec3dot1-vaccines-12-00072">
        <title>3.1. Patient Characteristics</title>
        <p>Five hundred and fourteen hospitalized patients were enrolled in the study. Among them, 288 (56.1%) had not received any COVID-19 vaccination, while 226 (43.9%) had received at least one vaccine dose. <xref rid="vaccines-12-00072-t001" ref-type="table">Table 1</xref> illustrates the vaccination schemes received. It is evident that most patients were unvaccinated, followed by those vaccinated with ChAdOx1-S (Oxford-AstraZeneca) and BNT162b2 (Pfizer—BioNTech). For the analyses of clinical evolution and prognosis, only these three patient subgroups were considered, excluding those with an incomplete vaccination regimen (such as a single dose of ChAdOx1-S or BNT162b2 or less than 14 days since their second vaccine dose) or those who received other minimally represented vaccine types. <xref rid="vaccines-12-00072-t002" ref-type="table">Table 2</xref> displays the key clinical characteristics of the 462 patients included in subsequent analyses (<xref rid="vaccines-12-00072-t002" ref-type="table">Table 2</xref>). These patients collectively accounted for a total of 4455 days of hospital stay. Only two (0.43%) of these 462 patients reported having had a previous COVID-19 infection, so this characteristic was not included as a variable in the analyses.</p>
      </sec>
      <sec id="sec3dot2-vaccines-12-00072">
        <title>3.2. Differences in Clinical Characteristics between Vaccinated and Unvaccinated Individuals</title>
        <p><xref rid="vaccines-12-00072-t002" ref-type="table">Table 2</xref> compares various clinical characteristics at admission and during hospital stay between the groups of patients who were unvaccinated and those vaccinated with ChAdOx1-S or BNT162b2 (complete regimen, at least two doses). Vaccinated individuals exhibit more comorbidities (diabetes, hypertension, CKD, Charlson index, and low eGFR) than the unvaccinated. Notably, up to 90% of BNT162b2-vaccinated patients are aged over 60, whereas, in the unvaccinated or ChAdOx1-S-vaccinated groups, this age group represents 57% of patients. This aligns to the vaccination strategy in Mexico, where BNT162b2 vaccine was initially exclusively administered to healthcare personnel and those over 60, followed by the widespread administration of the ChAdOx1-S vaccine, with initial preference given to patients with comorbidities and those over 60 [<xref rid="B23-vaccines-12-00072" ref-type="bibr">23</xref>]. The body mass index (BMI) was not different between the three groups (<italic toggle="yes">p</italic> = 0.264, ANOVA test) (<xref rid="vaccines-12-00072-t002" ref-type="table">Table 2</xref>), so it would not be a factor that could differentiate the clinical evolution between them.</p>
        <p>In respect to the disease stage at hospital admission, ChAdOx1-S or BNT162b2-vaccinated individuals had a higher proportion of patients in the viral (early) stage compared to the unvaccinated (viral stage at 27.7%, 60.3%, and 45.0%, respectively, ANOVA <italic toggle="yes">p</italic> &lt; 0.001). They also have lower severity according to the NEWS-2 scale (7.7 ± 3.5, 6.5 ± 3.1, 6.6 ± 3.0, respectively, ANOVA <italic toggle="yes">p</italic> = 0.003) (<xref rid="vaccines-12-00072-t002" ref-type="table">Table 2</xref>). However, BNT162b2-vaccinated patients tend to have a higher proportion of patients admitted in the hyperinflammatory stage and a higher PSI score than the other groups, although, these differences were not statistically significant (see <xref rid="vaccines-12-00072-t002" ref-type="table">Table 2</xref>).</p>
        <p>Regarding the treatment regimens received during hospitalization, there were no differences between the groups in the use of paracetamol, anticoagulants, antibiotics, steroids, diuretics, or amine support. However, unvaccinated individuals were more frequently required mechanical ventilation compared to those vaccinated with ChAdOx1-S or BNT162b2 (38.1%, 23.3%, 21.8%, respectively, <italic toggle="yes">p</italic> = 0.002, ANOVA test). ChAdOx1-S-vaccinated patients had a higher incidence of AKI compared to the unvaccinated (<italic toggle="yes">p</italic> = 0.001) and BNT162b2-vaccinated (<italic toggle="yes">p</italic> = 0.004) individuals (35.6%, 16.7%, 18.7%, respectively), while the latter two groups did not significantly differ (<italic toggle="yes">p</italic> = 0.545). Consequently, the need for hemodialysis was more frequent in ChAdOx1-S-vaccinated patients (ChAdOx1-S vs. unvaccinated <italic toggle="yes">p</italic> = 0.015, ChAdOx1-S vs. BNT162b2 <italic toggle="yes">p</italic> = 0.003, BNT162b2 vs. unvaccinated <italic toggle="yes">p</italic> = 0.139) (see <xref rid="vaccines-12-00072-t002" ref-type="table">Table 2</xref>).</p>
        <p>During the study period (January 2021 to December 2022), various variants of COVID-19 affected the population of Mexico (research site) [<xref rid="B24-vaccines-12-00072" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-12-00072" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-00072" ref-type="bibr">26</xref>]. Considering the predominant variants, <xref rid="vaccines-12-00072-f002" ref-type="fig">Figure 2</xref> shows that the severity of the disease did not vary significantly in non-vaccinated patients during different periods (<italic toggle="yes">p</italic> = 0.080, ANOVA test). However, in individuals vaccinated with ChAdOx1-S (<italic toggle="yes">p</italic> &lt; 0.001, ANOVA test) and BNT162b2 (<italic toggle="yes">p</italic> &lt; 0.001, ANOVA test), there were significant variations between periods, with higher severity observed during periods when the Delta variant was predominant in the population.</p>
      </sec>
      <sec id="sec3dot3-vaccines-12-00072">
        <title>3.3. Hospitalization Days and Survival</title>
        <p>The mortality among fully vaccinated individuals was 36.2%, compared to 52.2% among the unvaccinated (<italic toggle="yes">p</italic> &lt; 0.001). <xref rid="vaccines-12-00072-t003" ref-type="table">Table 3</xref> displays the hospital stay details. The number of hospitalization days did not differ significantly among the three groups (<italic toggle="yes">p</italic> = 0.207). Overall, the highest mortality was observed in the unvaccinated group (52.6%), followed by those vaccinated with ChAdOx1-S (41.1%) and BNT162b2 (31.7%) (see <xref rid="vaccines-12-00072-t003" ref-type="table">Table 3</xref>). In patients aged ≥ 60 years, BNT162b2-vaccinated individuals had significantly lower mortality (33.0%) compared to those vaccinated with ChAdOx1-S (50.0%) or the unvaccinated (61.8%) (see <xref rid="vaccines-12-00072-t003" ref-type="table">Table 3</xref>).</p>
        <p>BNT162b2-vaccinated individuals also experienced lower mortality than the unvaccinated when their admission disease was severe (pulmonary or hyperinflammatory phase) (43.4% vs. 59.8%, <italic toggle="yes">p</italic> = 0.010) or with a worse prognosis (PSI score &gt; 120) (67.6% vs. 85.8%, <italic toggle="yes">p</italic> = 0.016) (see <xref rid="vaccines-12-00072-t003" ref-type="table">Table 3</xref>). In contrast, among patients with these characteristics, those vaccinated with ChAdOx1-S did not statistically differ from the unvaccinated (see <xref rid="vaccines-12-00072-t003" ref-type="table">Table 3</xref>).</p>
        <p>In a 40-day survival follow-up (Kaplan-Meier curves), significant differences were observed among various vaccination schemes (<italic toggle="yes">p</italic> = 0.003, multigroup log-rank test). BNT162b2-vaccinated individuals exhibited higher survival rate (mean 30.3 days, 95% CI 27.3–33.2, survivors 68.3%), while the unvaccinated had lower survival rate (mean 24.3 days, 95% CI 22.5–26.1, survivors 47.4%), with ChAdOx1-S-vaccinated individuals falling in between (mean 27.2 days, 95% CI 23.6–30.8, survivors 58.9%) (see <xref rid="vaccines-12-00072-f003" ref-type="fig">Figure 3</xref>A). Stratifying patients based on different characteristics revealed differences among groups for those hospitalized in advanced stages of the disease (pulmonary and hyperinflammatory) (<italic toggle="yes">p</italic> = 0.036, multigroup log-rank test). BNT162b2-vaccinated individuals showed higher survival rate (mean 26.6 days, 95% CI 22.3–31.1, survivors 56.6%), while ChAdOx1-S-vaccinated individuals had lower survival rate (mean 17.4 days, 95% CI 11.9–22.8, survivors 27.6%), and the unvaccinated drop in between (median 22.0 days, 95% CI 19.9–24.1, survivors 40.2%) (see <xref rid="vaccines-12-00072-f003" ref-type="fig">Figure 3</xref>B).</p>
        <p>On the other hand, among patients hospitalized at an early stage (viral phase), no significant differences in survival were found based on their vaccination scheme (<italic toggle="yes">p</italic> = 0.124, multigroup log-rank test). However, BNT162b2 or ChAdOx1-S-vaccinated patients had higher survival rate (not statistically significant) than the unvaccinated (80.9%, 79.5%, and 65.8%, respectively) (see <xref rid="vaccines-12-00072-f003" ref-type="fig">Figure 3</xref>C). According to the PSI score, in patients hospitalized with values below 120 (indicating a better prognosis than higher scores, <xref rid="vaccines-12-00072-f003" ref-type="fig">Figure 3</xref>D), BNT162b2-vaccinated individuals had higher survival rate (mean 36.7 days, 95% CI 34.3–39.1, survivors 88.9%), while the unvaccinated had lower survival (mean 30.1 days, 95% CI 27.9–32.3, survivors 67.8%), with ChAdOx1-S-vaccinated individuals falling in between (median 33.6 days, 95% CI 30.0–37.2, survivors 78.3%) (<italic toggle="yes">p</italic> = 0.001, multigroup log-rank test). Among patients with a very poor prognosis at admission (PSI &gt; 120), no significant differences in survival were found based on their vaccination scheme (<italic toggle="yes">p</italic> = 0.395, multigroup log-rank test). However, BNT162b2 or ChAdOx1-S-vaccinated patients had better survival rates than the unvaccinated (32.4%, 24.0%, and 14.2%, respectively) (see <xref rid="vaccines-12-00072-f003" ref-type="fig">Figure 3</xref>E).</p>
        <p>Among patients aged 60 years or older (<xref rid="vaccines-12-00072-f003" ref-type="fig">Figure 3</xref>F), BNT162b2-vaccinated individuals had the highest survival (mean 29.9 days, 95% CI 26.8–33.2, survivors 67.0%), while the unvaccinated had the lowest survival (mean 21.7 days, 95% CI 19.3–24.0, survivors 38.2%), with ChAdOx1-S-vaccinated individuals falling in between (mean 25.0 days, 95% CI 20.3–29.7, survivors 50.0%) (<italic toggle="yes">p</italic> &lt; 0.001, multigroup log-rank test). Among patients younger than 60 years (<xref rid="vaccines-12-00072-f003" ref-type="fig">Figure 3</xref>F), no significant differences were found based on their vaccination scheme (<italic toggle="yes">p</italic> = 0.386, log-rank test), although once again, BNT162b2 or ChAdOx1-S-vaccinated patients had better survival rates than the unvaccinated (80.0%, 71.0%, and 59.7%, respectively).</p>
      </sec>
      <sec id="sec3dot4-vaccines-12-00072">
        <title>3.4. Risk Factors for Death in Hospitalized Patients with COVID-19, including Vaccination Schedule</title>
        <p><xref rid="vaccines-12-00072-t004" ref-type="table">Table 4</xref> presents a multivariate generalized linear mixed model with binary logistic regression analysis that identifies factors associated with death in patients hospitalized with COVID-19, including the impact of their vaccination schedule. This analysis included factors that were found to be different among groups according to <xref rid="vaccines-12-00072-t002" ref-type="table">Table 2</xref>. The statistical model also incorporated the period of the pandemic during which the patient was hospitalized as a random effect (see Materials and Methods section). Regarding pre-existing conditions or conditions at hospital admission, smoking (RR 4.5, 95% CI 2.0–10.1, <italic toggle="yes">p</italic> &lt; 0.001), and advanced disease phase (pulmonary/hyperinflammatory) significantly increased the risk of death (RR 4.01, 95% CI 2.4–6.5, <italic toggle="yes">p</italic> &lt; 0.001). During hospitalization, elevated indices of severe disease, including NEWS-2 score ≥ 12 (RR 3.56, 95% CI 1.6–7.7, <italic toggle="yes">p</italic> = 0.001), PSI score &gt; 120 (RR 8.14, 95% CI 5.0–13.1, <italic toggle="yes">p</italic> &lt; 0.001), the need for mechanical ventilation (RR 3.74, 95% CI 1.8–7.3, <italic toggle="yes">p</italic> &lt; 0.001), and neutrophils ≥ 8 × 10e<sup>3</sup>/uL (RR 3.76, 95% CI 2.3–6.0, <italic toggle="yes">p</italic> &lt; 0.001), were identified as risk factors (see <xref rid="vaccines-12-00072-t004" ref-type="table">Table 4</xref>). Additionally, having lymphocytes ≥680/uL (RR 0.53, 95% CI 0.3–0.8, <italic toggle="yes">p</italic> = 0.007) or ALT &gt; 45 UL (RR 0.45, 95% CI 0.2–0.8, <italic toggle="yes">p</italic> = 0.005) were identified as protective factors. BNT162b2-vaccinated individuals had a 2.4-times reduced risk of death (RR 0.41, 95% CI 0.2–0.8, <italic toggle="yes">p</italic> = 0.008), whereas ChAdOx1-S-vaccinated individuals showed no significant difference in the risk of death compared to the unvaccinated (RR 1.04, 95% CI 0.5–2.3, <italic toggle="yes">p</italic> = 0.915) (see <xref rid="vaccines-12-00072-t004" ref-type="table">Table 4</xref>). The receipt of a booster dose was also not associated with the risk of death (<italic toggle="yes">p</italic> = 0.247) (see <xref rid="vaccines-12-00072-t004" ref-type="table">Table 4</xref>). Combining the patients vaccinated with BNT162b2 and whereas ChAdOx1-S into a single group, it is observed that patients in this group reduce their risk of death by almost half, with a RR value of 0.54 (95% CI 0.30–0.97), being a congruent value as it is located between the RR values of BNT162b2 (0.41) and whereas ChAdOx1-S (1.04). It is important to highlight those only patients with a complete vaccination schedule (at least two doses) were considered, and all booster vaccinations were administered as ChAdOx1-S, irrespective of the initial vaccination scheme.</p>
      </sec>
      <sec id="sec3dot5-vaccines-12-00072">
        <title>3.5. Clinical Differences between Those Vaccinated with BNT162b2 and ChAdOx1-S</title>
        <p>In <xref rid="vaccines-12-00072-t005" ref-type="table">Table 5</xref>, a multivariate analysis is shown to determine the probability of being vaccinated with BNT162b2 according to the presence of various characteristics, compared to patients vaccinated with ChAdOx1-S [<xref rid="B21-vaccines-12-00072" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-12-00072" ref-type="bibr">22</xref>]. It is observed that being &gt; 60 years old, being admitted in an advanced phase of the disease (pulmonary/hyperinflammatory) and having a PSI score &gt; 120 were factors associated with being vaccinated with BNT162b2, in comparison to patients vaccinated with ChAdOx1-S. Conversely, having ferritin levels &gt;810 ng/mL, receiving an additional vaccine dose, or experiencing death were variables less likely to be present in those vaccinated with BNT162b2 (see <xref rid="vaccines-12-00072-t005" ref-type="table">Table 5</xref>). This makes it evident that patients vaccinated with BNT162b2 had 3.7-times lower odds of death than patients vaccinated with ChAdOx1-S, despite being older and having a more advanced and severe disease at admission. Among the hematological or inflammatory parameters that could explain these differences between different vaccination schemes, the protection against elevated ferritin levels in patients with BNT162b2 stands out.</p>
        <p>In <xref rid="vaccines-12-00072-t006" ref-type="table">Table 6</xref>, a multivariate analysis is shown to determine the probability of being vaccinated with Pfizer according to the presence of various characteristics, compared to non-vaccinated patients. It shows that being over 60 years old, male, having a higher comorbidity index, and having higher levels of neutrophils and lymphocytes were factors associated with being vaccinated with BNT162b2 compared to non-vaccinated patients. On the contrary, not smoking, experiencing less acute kidney injury during hospitalization, or dying were variables less likely to be present in BNT162b2-vaccinated individuals (see <xref rid="vaccines-12-00072-t006" ref-type="table">Table 6</xref>). This makes it clear that BNT162b2-vaccinated patients died 2.6-times less than non-vaccinated patients, despite being older and having more comorbidities. Having less lymphopenia and the presence of acute kidney injury appear to be the most relevant factors that could explain the lower mortality in BNT162b2-vaccinated patients compared to non-vaccinated individuals.</p>
      </sec>
      <sec id="sec3dot6-vaccines-12-00072">
        <title>3.6. Evolution of Some Clinical Parameters during the First 6 Days</title>
        <p>The evolution of some risk factors for mortality (see <xref rid="vaccines-12-00072-t004" ref-type="table">Table 4</xref>) during the first 6 days of hospitalization was analyzed. In <xref rid="vaccines-12-00072-f004" ref-type="fig">Figure 4</xref>A, the NEWS-2 score is higher in non-vaccinated patients at admission compared to vaccinated patients (<italic toggle="yes">p</italic> = 0.026; and <italic toggle="yes">p</italic> = 0.018; compared to ChAdOx1-S and BNT162b2, respectively). However, on day 4, patients vaccinated with ChAdOx1-S begin to increase this score, and those vaccinated with BNT162b2 remain with the lowest levels throughout all the days analyzed. On day 6, the NEWS-2 score was higher in non-vaccinated patients, followed by those vaccinated with ChAdOx1-S and BNT162b2 (8.4 ± 4.1, 7.3 ± 3.6, 5.8 ± 3.9, respectively). This is consistent with the proportion of patients who ultimately died in each patient group. The PSI (<xref rid="vaccines-12-00072-f004" ref-type="fig">Figure 4</xref>B) was initially higher in patients vaccinated with BNT162b2, but as the days progressed, non-vaccinated patients and those vaccinated with ChAdOx1-S began to increase their PSI until, by day 6, there were no longer differences between the groups (118.7 ± 46.1, 122.6 ± 39.3, 124.1 ± 41.9, respectively). The absolute values of lymphocytes (<xref rid="vaccines-12-00072-f004" ref-type="fig">Figure 4</xref>C) were, on average, always lower in non-vaccinated patients compared to vaccinated ones, with no differences observed between the two vaccine types. In terms of the PLR levels, non-vaccinated patients clearly had the highest values (<xref rid="vaccines-12-00072-f004" ref-type="fig">Figure 4</xref>D). Finally, the serum level of ferritin (<xref rid="vaccines-12-00072-f004" ref-type="fig">Figure 4</xref>E) in patients vaccinated with BNT162b2 was on average clearly lower than the value of non-vaccinated or ChAdOx1-S-vaccinated patients. Repeated measurement data for these variables were analyzed using multivariate linear mixed-effects models, confirming a significant difference in the BNT162b2 group compared to the other two groups in PSI index and ferritin levels, while the parameters of NEWS-2 score, lymphocytes, and PLR behaved similarly in both vaccinated groups, with significant differences compared to the values of non-vaccinated patients (see <xref rid="vaccines-12-00072-t007" ref-type="table">Table 7</xref>).</p>
      </sec>
      <sec id="sec3dot7-vaccines-12-00072">
        <title>3.7. Predictors of Death Based on Vaccination Status</title>
        <p><xref rid="vaccines-12-00072-t008" ref-type="table">Table 8</xref> and <xref rid="app1-vaccines-12-00072" ref-type="app">Table S1</xref> present various clinical useful factors for predicting mortality in different patient groups based on their vaccination status. The area under the ROC curve (AUC) was calculated to determine the optimal cut-off point for each variable in predicting death within each patient group. The Pneumonia Severity Index (PSI) emerged as a relevant predictor of death toll across all groups, with significantly lower AUC values in BNT162b2-vaccinated patients compared to those vaccinated with ChAdOx1-S (<italic toggle="yes">p</italic> = 0.043) or unvaccinated individuals (<italic toggle="yes">p</italic> &lt; 0.001). It is noteworthy that the cut-off points for predicting death were higher in BNT162b2 or ChAdOx1-S-vaccinated individuals compared to those the unvaccinated (124.5, 123.5, and 118.0, respectively), demonstrating good sensitivity (close to 0.80 in all groups) but low specificity. This indicates that vaccinated patients need to reach a higher severity to predict their mortality. Regarding oxygen levels, the AUCs were approximately 0.35 in all groups, showing no differences among them (<italic toggle="yes">p</italic> &gt; 0.05 for all intergroup comparisons). However, BNT162b2 or ChAdOx1-S-vaccinated patients had higher cut-off points than the unvaccinated individuals (82.5%, 84.5%, and 74.0%, respectively) to predict patient survival or mortality with high sensitivity and specificity in all groups, although, it was higher in the unvaccinated (see <xref rid="vaccines-12-00072-t007" ref-type="table">Table 7</xref>). This aligns to arterial pH analysis, where AUC values were significant in predicting death in all groups (AUC 0.25, 0.29, and 0.37; in the unvaccinated, ChAdOx1-S, or BNT162b2, respectively). However, the cut-off point was more acidic in the unvaccinated (pH 7.2305) compared to ChAdOx1-S or BNT162b2-vaccinated individuals (pH 7.3100, and 7.3005, respectively) (see <xref rid="app1-vaccines-12-00072" ref-type="app">Table S1</xref>). Arterial pH was significantly lower on average in unvaccinated or ChAdOx1-S-vaccinated patients compared to BNT162b2-vaccinated patients (7.339 ± 0.16, 7.333 ± 0.15, and 7.360 ± 0.14, respectively, <italic toggle="yes">p</italic> &lt; 0.05 for both comparisons, see <xref rid="vaccines-12-00072-t008" ref-type="table">Table 8</xref>). This suggests that lung damage might be more relevant in predicting death toll in unvaccinated patients than in vaccinated ones.</p>
        <p>Regarding immune system cells, as shown in <xref rid="vaccines-12-00072-t007" ref-type="table">Table 7</xref>, vaccinated patients had significantly higher cell counts than the unvaccinated individuals. Simultaneously, it was observed that a deeper degree of lymphopenia was necessary to predict death in unvaccinated patients (cutoff: 535/µL) compared to ChAdOx1-S or BNT162b2-vaccinated groups (cutoff: 831/µL and 893/µL, respectively). On the other hand, for neutrophils to be a predicting factor for death, vaccinated patients needed to have neutrophilia (neutrophil count &gt; 7700/microliter), compared to a normal value in unvaccinated individuals (cutoff in ChAdOx1-S, BNT162b2, and unvaccinated: 9711, 9430, and 7311, respectively) (see <xref rid="vaccines-12-00072-t008" ref-type="table">Table 8</xref>). It has been previously reported that when neutrophilia is present in a hospitalized COVID-19 patient, an increased inflammatory status and cytokine storm occurs, and potential bacterial infections should be considered [<xref rid="B27-vaccines-12-00072" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-12-00072" ref-type="bibr">28</xref>]. An average neutrophil count of over 9100 cells/µL was found in patients with confirmed bacterial infection hospitalized for COVID-19. If we consider this value as a possible indicator of bacterial infection, it is found that days prior to hospital discharge, this factor was present in 49.2%, 64.6%, and 77.8% of deceased patients in unvaccinated, ChAdOx1-S-vaccinated, and BNT162b2-vaccinated individuals, respectively (<italic toggle="yes">p</italic> &lt; 0.001, Fisher’s exact test of 2 × 3 contingency table). This was significantly lower in deceased unvaccinated individuals compared to ChAdOx1-S-vaccinated (<italic toggle="yes">p</italic> = 0.036) and BNT162b2-vaccinated individuals (<italic toggle="yes">p</italic> &lt; 0.001), although, the two vaccinated groups were not statistically different (<italic toggle="yes">p</italic> = 0.105). With this, clinical differences between vaccinated and unvaccinated individuals are evident, indicating that neutrophilia seems to be a relevant factor in predicting death in vaccinated patients, suggesting that the presence of bacterial co-infection could be a more critical factor for mortality in vaccinated individuals.</p>
        <p>However, it is interesting to note differences between the two vaccinated groups, considering that individuals vaccinated with BNT162b2 have over 3.7-times less likelihood of dying compared to those vaccinated with ChAdOx1-S (see <xref rid="vaccines-12-00072-t005" ref-type="table">Table 5</xref>). In liver function tests, the enzyme LDH emerged as the most relevant parameter for predicting death toll in all groups. A significant difference in the AUC was observed between the ChAdOx1-S group and the BNT162b2 group (AUC 0.873 vs. 0.758, <italic toggle="yes">p</italic> = 0.002) and between the ChAdOx1-S group and the unvaccinated group (ChAdOx1-S vs. unvaccinated, AUC 0.873 vs. AUC 0.744, <italic toggle="yes">p</italic> &lt; 0.001) (<xref rid="vaccines-12-00072-t008" ref-type="table">Table 8</xref>). However, it is important to mention that unvaccinated individuals have a higher cut-off point than those vaccinated with ChAdOx1-S or BNT162b2 (367, 333, and 325 IU/L, respectively) (<xref rid="vaccines-12-00072-t008" ref-type="table">Table 8</xref>). LDH only demonstrates good sensitivity (0.78) with little specificity for predicting death in those vaccinated with ChAdOx1-S, while in those vaccinated with BNT162b2 or unvaccinated, its sensitivity is much lower (0.61 and 0.68, respectively) (<xref rid="vaccines-12-00072-t008" ref-type="table">Table 8</xref>). On the other hand, the enzymes ALP, ALT, and AST were not significant predicting factors in the ChAdOx1-S-vaccinated group, but they were in those vaccinated with BNT162b2 and the unvaccinated group. However, this does not imply that these enzymes are not relevant for ChAdOx1-S-vaccinated patients, as this group had, on average, higher serum levels of ALP, ALT, and AST (see <xref rid="vaccines-12-00072-t009" ref-type="table">Table 9</xref>). This could indicate that the values of these enzymes were elevated in both those who died and those who survived, making it an irrelevant parameter for distinguishing between these outcomes in ChAdOx1-S-vaccinated patients.</p>
        <p>Regarding renal function, eGFR upon hospital admission showed no differences between patients vaccinated with ChAdOx1-S or BNT162b2, but these groups had higher values compared to the unvaccinated individuals (see <xref rid="vaccines-12-00072-t002" ref-type="table">Table 2</xref>). The eGFR value was useful for predicting death in all groups, with significantly different AUCs between the unvaccinated and ChAdOx1-S groups (0.318 vs. 0.425, <italic toggle="yes">p</italic> = 0.001) and between the unvaccinated and BNT162b2 groups (0.316 vs. 0.431, <italic toggle="yes">p</italic> &lt; 0.001), but no difference in AUCs between the ChAdOx1-S and BNT162b2 groups (<italic toggle="yes">p</italic> = 0.865) (<xref rid="vaccines-12-00072-t008" ref-type="table">Table 8</xref>). However, the cutoff values were observed to be very different, at 75.2, 36.3, and 60.0 mL/min/1.73m<sup>2</sup> in the unvaccinated, ChAdOx1-S-vaccinated, and BNT162b2-vaccinated groups, respectively (see <xref rid="vaccines-12-00072-t008" ref-type="table">Table 8</xref>). This may suggest that severe loss of renal function as a predictor of death only occurred in the ChAdOx1-S-vaccinated group (eGFR &lt; 36), while the loss of renal function for predicting death was mild to moderate in the BNT162b2 and unvaccinated groups, indicating that other factors were likely more relevant in these latter two groups.</p>
        <p>In markers of inflammation, there was a difference in AUCs between ChAdOx1-S and BNT162b2 for PCR (<italic toggle="yes">p</italic> = 0.002), ferritin (<italic toggle="yes">p</italic> = 0.032), and VCP (&lt;0.001), with these three factors being significant predictors of death in BNT162b2-vaccinated patients but not in those vaccinated with ChAdOx1-S (see <xref rid="vaccines-12-00072-t008" ref-type="table">Table 8</xref> and <xref rid="app1-vaccines-12-00072" ref-type="app">Table S1</xref>). These three factors were also relevant for predicting death in unvaccinated patients. On the other hand, D-dimer was a useful and similar parameter for predicting death significantly in all groups (see <xref rid="vaccines-12-00072-t008" ref-type="table">Table 8</xref>). With all the above, it can be observed that there are some different factors between patients vaccinated with BNT162b2 or ChAdOx1-S. For those vaccinated with BNT162b2, a combination of markers of liver damage (AST, ALT, ALP, and LDH) and certain inflammation markers (ferritin, PCR, and VCP) were useful for predicting patient death, but not in those vaccinated with ChAdOx1-S. This does not mean that all these markers are low in ChAdOx1-S-vaccinated patients; on the contrary, ALP, ferritin, and D-dimer are significantly elevated in this group compared to those vaccinated with BNT162b2, with the rest of the liver enzymes and CRP following the same trend (see <xref rid="vaccines-12-00072-t009" ref-type="table">Table 9</xref>). On the other hand, the average values of ferritin, CRP, D-dimer and LDH do not differ between patients vaccinated with ChAdOx1-S and those unvaccinated. Additionally, the average values of ALT and ALP were significantly higher in patients with ChAdOx1-S than in those unvaccinated (see <xref rid="vaccines-12-00072-t009" ref-type="table">Table 9</xref>).</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="sec4-vaccines-12-00072">
      <title>4. Discussion</title>
      <p>In the context of a population with one of the highest mortality rates worldwide for COVID-19 hospitalized patients, there were differences in the proportion of deaths based on the vaccination scheme. Those who died in higher proportion were the unvaccinated (52.6%), followed by those vaccinated with ChAdOx1-S (41.1%) and those vaccinated with BNT162b2 (31.7%) (vaccination schemes with at least two doses and at least 14 days elapsed since their second dose). The lower mortality of those vaccinated with BNT162b2 occurred even though these patients were older and had higher severity (higher PSI) at the time of hospital admission. Those vaccinated with ChAdOx1-S or BNT162b2 had nearly half the risk of dying from the disease compared to the unvaccinated (adjusted RR 0.54, 95% CI 0.30–0.97, <italic toggle="yes">p</italic> = 0.041). However, when stratifying by vaccine type, those vaccinated with BNT162b2 had 2.4-times less risk of death compared to the unvaccinated (adjusted RR 0.41, CI95% 0.2–0.8, <italic toggle="yes">p</italic> = 0.008), while those vaccinated with ChAdOx1-S did not differ from the unvaccinated in terms of their risk of death (adjusted RR 1.04, CI95% 0.5–2.3, <italic toggle="yes">p</italic> = 0.915). This suggests differences in the clinical outcomes of patients based on the administered vaccine.</p>
      <p>The reduction in the risk of death by vaccination in hospitalized COVID-19 patients aligns with previous reports from Croatia [<xref rid="B8-vaccines-12-00072" ref-type="bibr">8</xref>] and Argentina-Spain [<xref rid="B7-vaccines-12-00072" ref-type="bibr">7</xref>]. However, other studies have not shown differences in mortality between vaccinated and unvaccinated patients in populations from the United States [<xref rid="B9-vaccines-12-00072" ref-type="bibr">9</xref>], Israel [<xref rid="B10-vaccines-12-00072" ref-type="bibr">10</xref>], or France [<xref rid="B11-vaccines-12-00072" ref-type="bibr">11</xref>]. Even a study conducted in Poland suggests that hospitalized patients may have a higher mortality after receiving one or two vaccine doses [<xref rid="B12-vaccines-12-00072" ref-type="bibr">12</xref>]. Huespe IA et al. (2023) mention that these contradictory results may be due to confounding variables, especially differences in the proportion and severity of comorbidities, generally higher in vaccinated groups at the beginning of the pandemic [<xref rid="B7-vaccines-12-00072" ref-type="bibr">7</xref>]. Differences among subgroups of populations can also lead to variations in the immune response to vaccines, which is progressively lower with older age and a higher prevalence of comorbidities [<xref rid="B29-vaccines-12-00072" ref-type="bibr">29</xref>].</p>
      <p>Among studies that have found that vaccination reduces mortality in hospitalized patients, one points out that those vaccinated with ChAdOx1-S (and other vaccines with adenoviral vectors) have lower mortality than those vaccinated with BNT162b2 [<xref rid="B8-vaccines-12-00072" ref-type="bibr">8</xref>], while another observed that those vaccinated with BNT162b2 had a greater reduction in mortality (OR 0.37; 95% CI: 0.23–0.59), followed by those vaccinated with ChAdOx1-S (OR 0.42; 95% CI: 0.20–0.86) [<xref rid="B7-vaccines-12-00072" ref-type="bibr">7</xref>]. In the first study, Busic et al. (2022) discuss that those vaccinated with BNT162b2 could have higher mortality than those vaccinated with ChAdOx1-S because mRNA vaccines (such as Pfizer—BioNTech) were the first vaccines to be administered, having preference for the older population and among selected patients with unfavorable prognostic characteristics [<xref rid="B7-vaccines-12-00072" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-00072" ref-type="bibr">8</xref>]. In the present report from Mexico, something similar happened in the vaccination strategy, with older patients and those with a higher index of comorbidities initially vaccinated and using BNT162b2. Therefore, patients vaccinated with BNT162b2 had more adverse characteristics and higher severity at the time of hospital admission, especially during periods when the Delta variant was one of the predominant strains in the population (see <xref rid="vaccines-12-00072-f002" ref-type="fig">Figure 2</xref>). However, even with a worse prognosis, those vaccinated with BNT162b2 had lower mortality in absolute numbers. In the analysis adjusting for variables such as age, sex, morbidity, severity, as well as, the pandemic period to consider variations in different waves (as a random effect), it was found that those vaccinated with BNT162b2 reduce the risk of death by 2.4-times compared to the unvaccinated, while those vaccinated with ChAdOx1-S did not differ from the unvaccinated ones in adjusted risk of death (see <xref rid="vaccines-12-00072-t004" ref-type="table">Table 4</xref>). However, as mentioned above, both those vaccinated with ChAdOx1-S and BNT162b2 reduce the overall percentage of death compared to those not vaccinated (41.1%, 31.7%, and 52.6%, respectively).</p>
      <p>In hospitalized patients, it was observed that receiving either the ChAdOx1-S or BNT162b2 vaccine contributes to higher lymphocyte counts and lower Platelet-to-Lymphocyte Ratios (PLR) compared to the unvaccinated group (<xref rid="vaccines-12-00072-f004" ref-type="fig">Figure 4</xref>, <xref rid="vaccines-12-00072-t002" ref-type="table">Table 2</xref>, <xref rid="vaccines-12-00072-t007" ref-type="table">Table 7</xref> and <xref rid="vaccines-12-00072-t009" ref-type="table">Table 9</xref>). Vaccination prevented severe hypoxemia from being the most sensitive and specific factor for predicting death, as observed in the unvaccinated group. This aligns to the improved survival rates found in both vaccinated groups. It is noteworthy that in the vaccinated individuals, neutrophilia serves as a predictive factor for death, suggesting that a concomitant bacterial infection might be a relevant factor leading to mortality in the vaccinated group. However, individuals vaccinated with BNT162b2 have a lower risk of death than those vaccinated with ChAdOx1-S (<xref rid="vaccines-12-00072-t005" ref-type="table">Table 5</xref>). This may be attributed to the additional observation that, on average, individuals vaccinated with BNT162b2 exhibit less impairment in markers of hepatic damage, lower levels of certain inflammatory markers (such as serum ferritin), and lower levels of D-dimer compared to those vaccinated with ChAdOx1-S or the unvaccinated group.</p>
      <p>The vaccines appear to induce a more robust immune response against severe/critical COVID-19 infection, leading to increased survival. The results suggest that more severe damage to other organs or systems, in addition to the lungs, would be necessary to predict death in vaccinated patients (<xref rid="vaccines-12-00072-t008" ref-type="table">Table 8</xref>, <xref rid="vaccines-12-00072-t009" ref-type="table">Table 9</xref> and <xref rid="app1-vaccines-12-00072" ref-type="app">Table S1</xref>). However, the ChAdOx1-S vaccine has a less beneficial effect than BNT162b2 in hospitalized patients. One possible explanation for this could be a lower stimulation of the immune system against COVID-19, resulting in lower survival rates in severe patients. It has been previously demonstrated that the efficacy for preventing disease or severe disease is higher for BNT162b2 compared to ChAdOx1-S (95–87.5% vs. 70%, respectively) [<xref rid="B3-vaccines-12-00072" ref-type="bibr">3</xref>], which aligns with a lower neutralization of SARS-CoV-2 by serum from individuals vaccinated with ChAdOx1-S compared to serum from BNT162b2-vaccinated individuals [<xref rid="B3-vaccines-12-00072" ref-type="bibr">3</xref>]. Another potential cause could be that using an adenoviral vector as a vehicle to stimulate immunity may limit some vaccine benefits. Exposure to adenovirus in preclinical models has led to long-term effects, including adverse metabolic, morphological (hepatic), and functional changes, with significantly high levels of serum inflammation markers [<xref rid="B30-vaccines-12-00072" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-12-00072" ref-type="bibr">31</xref>]. It has been postulated that these chronic adenoviral effects, including prolonged inflammatory responses [<xref rid="B32-vaccines-12-00072" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-12-00072" ref-type="bibr">33</xref>], could occur with their application in gene therapy [<xref rid="B30-vaccines-12-00072" ref-type="bibr">30</xref>] or after their use in COVID-19 vaccines [<xref rid="B34-vaccines-12-00072" ref-type="bibr">34</xref>]. However, these are unverified hypotheses that need to be investigated in future research, as the emergency authorization of COVID-19 vaccines (adenoviral or mRNA) may not have fully addressed certain safety aspects [<xref rid="B32-vaccines-12-00072" ref-type="bibr">32</xref>,<xref rid="B35-vaccines-12-00072" ref-type="bibr">35</xref>].</p>
      <p>A strength of the present study was the adjustment for comorbidities, severity, and other relevant factors that can affect the death prognosis of patients, as well as the analysis with repeated measurements of various clinical factors during hospitalization. Additionally, the temporality of the pandemic (month of hospital admission) was considered in the statistical model used. Another relevant aspect is that the effect of vaccination was analyzed from different points of view (mortality rate, survival curves, association analysis, ROC curves, evaluation of hematological and biochemical parameters), so conclusions can be reached based multiple aspects and not with the result of a single analysis. Undoubtedly, evaluating the effect of vaccination in a population of hospitalized patients with high mortality helps assess the potential impact of vaccines under very adverse prognostic conditions, which is challenging to evaluate in other populations or periods of the pandemic.</p>
      <p>Considering the results obtained in this study, it is imperative to highlight that these findings reinforce the efficacy of COVID-19 vaccines in reducing hospital fatalities, in addition to the previously reported reduction in severity and hospitalizations [<xref rid="B3-vaccines-12-00072" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-12-00072" ref-type="bibr">4</xref>]. However, addressing these findings with caution is fundamental to avoid misinterpretations that could be misused for anti-vaccine purposes. It is crucial to emphasize that this study not only highlights a significant decrease in the risk of mortality for vaccinated individuals, especially in populations with increased health risks, but also underscores notable differences among the various types of vaccines used. The findings highlight the crucial and beneficial role of vaccination, adding to what was previously described to reduce symptoms and the risks of hospital admission and death [<xref rid="B36-vaccines-12-00072" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-12-00072" ref-type="bibr">37</xref>]. These collective results underscore the current importance of vaccination efforts, considering variations in populations and the types of vaccines used.</p>
      <p>The present study also had limitations. The number of patients did not allow for evaluations and comparisons between patients with a single vaccine dose. Similarly, the mortality in patients vaccinated with ChAdOx1-S was intermediate between the unvaccinated and those vaccinated with BNT162b2, so in various analyses, statistically significant differences between ChAdOx1-S and the other two groups were not observed. Future analyses with a larger number of individuals are desirable to better observe the differences between these groups. Additional facets of the investigation pertinent to the studied population, such as the types of vaccines administered and who was given priority for vaccination at the beginning of the pandemic in Mexico, did not allow for the evaluation of other vaccine brands and types as well as their effects on various population strata with fewer comorbidities. Likewise, only 8.9% of the hospitalized patients included had a booster vaccine, making a detailed analysis of this subgroup unfeasible. It is important to note that exploring this aspect was limited in the current study. Future research efforts should consider a more in-depth examination of this subgroup, especially in the context of different COVID variants.</p>
    </sec>
    <sec sec-type="conclusions" id="sec5-vaccines-12-00072">
      <title>5. Conclusions</title>
      <p>In summary, in the context of a population of hospitalized patients with COVID-19 with a very adverse prognosis and very high mortality, patients vaccinated with BNT162b2 had a lower risk of death compared to those vaccinated with ChAdOx1-S and the unvaccinated. Patients vaccinated with ChAdOx1-S had an intermediate mortality rate between BNT162b2-vaccinated patients (who had the lowest mortality) and the unvaccinated group (with the highest mortality). The protective effect observed in vaccinated patients can be explained by higher lymphocyte counts and lower levels of some inflammation markers such as PLR. However, patients vaccinated with BNT162b2 additionally have lower values of other inflammation markers, such as ferritin and D-dimer. Unlike unvaccinated patients, it can be inferred that, in general, vaccinated patients require more extensive damage to other organs, in addition to lung damage, or other complications (such as concomitant bacterial infection) to predict death toll. More studies on the effects of COVID-19 vaccination are necessary.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>The authors would like to thank Janet Diaz-Martinez from Florida International University (Miami, USA) and the contributions of Julio V. Barrios Nuñez from University of Colima (Colima, Mexico) for their assistance with English language editing.</p>
    </ack>
    <fn-group>
      <fn>
        <p><bold>Disclaimer/Publisher’s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p>
      </fn>
    </fn-group>
    <app-group>
      <app id="app1-vaccines-12-00072">
        <title>Supplementary Materials</title>
        <p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines12010072/s1">https://www.mdpi.com/article/10.3390/vaccines12010072/s1</uri>, Table S1. Cutoff scores, area under the curve (AUC), sensitivity, and specificity for various clinical measures examined in this study.</p>
        <supplementary-material id="vaccines-12-00072-s001" position="float" content-type="local-data">
          <media xlink:href="vaccines-12-00072-s001.zip">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
      </app>
    </app-group>
    <notes>
      <title>Author Contributions</title>
      <p>Conceptualization, M.A.M.-H., J.G.-E. and I.D.-E.; Methodology, M.A.R.-R., V.V.S.-L., C.A.S.-R., G.A.H.-F., J.D.-M., V.M., F.R.-L., M.L.M.-F., A.C.-L. and I.D.-E.; Software, M.A.M.-H., J.G.-E., I.P.R.-S. and I.D.-E.; Validation, M.A.R.-R., V.V.S.-L., C.A.S.-R., G.A.H.-F., J.D.-M., V.M., F.R.-L., M.L.M.-F. and I.D.-E.; Formal Analysis, M.A.M.-H., D.T.-J., I.P.R.-S., O.G.D.-E., A.C.-L. and I.D.-E.; Investigation, M.A.M.-H., J.G.-E. and I.D.-E.; Resources, M.A.M.-H., J.G.-E. and I.D.-E.; Data Curation, J.G.-E., M.A.M.-H., G.A.H.-F. and I.D.-E.; Writing—Original Draft Preparation, J.G.-E., M.A.M.-H., G.A.H.-F. and I.D.-E.; Writing—Review &amp; Editing, M.A.R.-R., V.V.S.-L., C.A.S.-R., G.A.H.-F., J.D.-M., V.M., F.R.-L., M.L.M.-F., O.G.D.-E., A.C.-L., D.T.-J. and I.D.-E.; Visualization, M.A.M.-H., J.G.-E. and I.D.-E.; Supervision, M.A.M.-H., J.G.-E. and I.D.-E.; Project Administration, M.A.M.-H., J.G.-E. and I.D.-E.; Funding Acquisition, M.A.M.-H., J.G.-E. and I.D.-E. All authors have read and agreed to the published version of the manuscript.</p>
    </notes>
    <notes>
      <title>Institutional Review Board Statement</title>
      <p>The study was conducted in accordance with the Declaration of Helsinki and approved by local health research committee of IMSS-Colima, Mexico (approval number R-2020-601-041, 24 September 2020).</p>
    </notes>
    <notes>
      <title>Informed Consent Statement</title>
      <p>The written informed consent of the patients was waived by the Ethics Committee and was not required from the patients included in the study, as it involved the analysis of information from a hospital database and did not imply any risk for the patients. The above is in accordance with national legislation (Article 23 of the regulations of the General Health Law on Health Research in Mexico) and institutional requirements. Patient confidentiality was protected.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data Availability Statement</title>
      <p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Conflicts of Interest</title>
      <p>The authors declare no conflict of interest.</p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="B1-vaccines-12-00072">
        <label>1.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahmani</surname><given-names>K.</given-names></name>
<name><surname>Shavaleh</surname><given-names>R.</given-names></name>
<name><surname>Forouhi</surname><given-names>M.</given-names></name>
<name><surname>Disfani</surname><given-names>H.F.</given-names></name>
<name><surname>Kamandi</surname><given-names>M.</given-names></name>
<name><surname>Oskooi</surname><given-names>R.K.</given-names></name>
<name><surname>Foogerdi</surname><given-names>M.</given-names></name>
<name><surname>Soltani</surname><given-names>M.</given-names></name>
<name><surname>Rahchamani</surname><given-names>M.</given-names></name>
<name><surname>Mohaddespour</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>The Effectiveness of COVID-19 Vaccines in Reducing the Incidence, Hospitalization, and Mortality from COVID-19: A Systematic Review and Meta-Analysis</article-title><source>Front. Public Health</source><year>2022</year><volume>10</volume><fpage>873596</fpage><?supplied-pmid 36091533?><pub-id pub-id-type="pmid">36091533</pub-id>
</element-citation>
      </ref>
      <ref id="B2-vaccines-12-00072">
        <label>2.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guzman-Esquivel</surname><given-names>J.</given-names></name>
<name><surname>Mendoza-Hernandez</surname><given-names>M.A.</given-names></name>
<name><surname>Guzman-Solorzano</surname><given-names>H.P.</given-names></name>
<name><surname>Sarmiento-Hernandez</surname><given-names>K.A.</given-names></name>
<name><surname>Rodriguez-Sanchez</surname><given-names>I.P.</given-names></name>
<name><surname>Martinez-Fierro</surname><given-names>M.L.</given-names></name>
<name><surname>Paz-Michel</surname><given-names>B.A.</given-names></name>
<name><surname>Murillo-Zamora</surname><given-names>E.</given-names></name>
<name><surname>Rojas-Larios</surname><given-names>F.</given-names></name>
<name><surname>Lugo-Trampe</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Clinical Characteristics in the Acute Phase of COVID-19 That Predict Long COVID: Tachycardia, Myalgias, Severity, and Use of Antibiotics as Main Risk Factors, While Education and Blood Group B Are Protective</article-title><source>Healthcare</source><year>2023</year><volume>11</volume><elocation-id>197</elocation-id><pub-id pub-id-type="doi">10.3390/healthcare11020197</pub-id><?supplied-pmid 36673565?><pub-id pub-id-type="pmid">36673565</pub-id>
</element-citation>
      </ref>
      <ref id="B3-vaccines-12-00072">
        <label>3.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mascellino</surname><given-names>M.T.</given-names></name>
<name><surname>Di Timoteo</surname><given-names>F.</given-names></name>
<name><surname>De Angelis</surname><given-names>M.</given-names></name>
<name><surname>Oliva</surname><given-names>A.</given-names></name>
</person-group><article-title>Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety</article-title><source>Infect. Drug Resist.</source><year>2021</year><volume>14</volume><fpage>3459</fpage><lpage>3476</lpage><pub-id pub-id-type="doi">10.2147/IDR.S315727</pub-id><?supplied-pmid 34511939?><pub-id pub-id-type="pmid">34511939</pub-id>
</element-citation>
      </ref>
      <ref id="B4-vaccines-12-00072">
        <label>4.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Havers</surname><given-names>F.P.</given-names></name>
<name><surname>Pham</surname><given-names>H.</given-names></name>
<name><surname>Taylor</surname><given-names>C.A.</given-names></name>
<name><surname>Whitaker</surname><given-names>M.</given-names></name>
<name><surname>Patel</surname><given-names>K.</given-names></name>
<name><surname>Anglin</surname><given-names>O.</given-names></name>
<name><surname>Kambhampati</surname><given-names>A.K.</given-names></name>
<name><surname>Milucky</surname><given-names>J.</given-names></name>
<name><surname>Zell</surname><given-names>E.</given-names></name>
<name><surname>Moline</surname><given-names>H.L.</given-names></name>
<etal/>
</person-group><article-title>COVID-19-Associated Hospitalizations among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022</article-title><source>JAMA Intern. Med.</source><year>2022</year><volume>182</volume><fpage>1071</fpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2022.4299</pub-id><?supplied-pmid 36074486?><pub-id pub-id-type="pmid">36074486</pub-id>
</element-citation>
      </ref>
      <ref id="B5-vaccines-12-00072">
        <label>5.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>D.</given-names></name>
<name><surname>Chang</surname><given-names>X.</given-names></name>
<name><surname>He</surname><given-names>Y.</given-names></name>
<name><surname>Tan</surname><given-names>K.J.K.</given-names></name>
</person-group><article-title>The Determinants of COVID-19 Morbidity and Mortality across Countries</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><fpage>5888</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-09783-9</pub-id><?supplied-pmid 35393471?><pub-id pub-id-type="pmid">35393471</pub-id>
</element-citation>
      </ref>
      <ref id="B6-vaccines-12-00072">
        <label>6.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ascencio-Montiel</surname><given-names>I.d.J.</given-names></name>
<name><surname>Ovalle-Luna</surname><given-names>O.D.</given-names></name>
<name><surname>Rascón-Pacheco</surname><given-names>R.A.</given-names></name>
<name><surname>Borja-Aburto</surname><given-names>V.H.</given-names></name>
<name><surname>Chowell</surname><given-names>G.</given-names></name>
</person-group><article-title>Comparative Epidemiology of Five Waves of COVID-19 in Mexico, March 2020–August 2022</article-title><source>BMC Infect. Dis.</source><year>2022</year><volume>22</volume><elocation-id>813</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-022-07800-w</pub-id><pub-id pub-id-type="pmid">36316634</pub-id>
</element-citation>
      </ref>
      <ref id="B7-vaccines-12-00072">
        <label>7.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huespe</surname><given-names>I.A.</given-names></name>
<name><surname>Ferraris</surname><given-names>A.</given-names></name>
<name><surname>Lalueza</surname><given-names>A.</given-names></name>
<name><surname>Valdez</surname><given-names>P.R.</given-names></name>
<name><surname>Peroni</surname><given-names>M.L.</given-names></name>
<name><surname>Cayetti</surname><given-names>L.A.</given-names></name>
<name><surname>Mirofsky</surname><given-names>M.A.</given-names></name>
<name><surname>Boietti</surname><given-names>B.</given-names></name>
<name><surname>Gómez-Huelgas</surname><given-names>R.</given-names></name>
<name><surname>Casas-Rojo</surname><given-names>J.M.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 Vaccines Reduce Mortality in Hospitalized Patients with Oxygen Requirements: Differences between Vaccine Subtypes. A Multicontinental Cohort Study</article-title><source>J. Med. Virol.</source><year>2023</year><volume>95</volume><fpage>e28786</fpage><pub-id pub-id-type="doi">10.1002/jmv.28786</pub-id><pub-id pub-id-type="pmid">37212340</pub-id>
</element-citation>
      </ref>
      <ref id="B8-vaccines-12-00072">
        <label>8.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Busic</surname><given-names>N.</given-names></name>
<name><surname>Lucijanic</surname><given-names>T.</given-names></name>
<name><surname>Barsic</surname><given-names>B.</given-names></name>
<name><surname>Luksic</surname><given-names>I.</given-names></name>
<name><surname>Busic</surname><given-names>I.</given-names></name>
<name><surname>Kurdija</surname><given-names>G.</given-names></name>
<name><surname>Barbic</surname><given-names>L.</given-names></name>
<name><surname>Kunstek</surname><given-names>S.</given-names></name>
<name><surname>Jelic</surname><given-names>T.</given-names></name>
<name><surname>Lucijanic</surname><given-names>M.</given-names></name>
</person-group><article-title>Vaccination Provides Protection from Respiratory Deterioration and Death among Hospitalized COVID-19 Patients: Differences between Vector and MRNA Vaccines</article-title><source>J. Med. Virol.</source><year>2022</year><volume>94</volume><fpage>2849</fpage><lpage>2854</lpage><pub-id pub-id-type="doi">10.1002/jmv.27666</pub-id><pub-id pub-id-type="pmid">35187697</pub-id>
</element-citation>
      </ref>
      <ref id="B9-vaccines-12-00072">
        <label>9.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tandon</surname><given-names>P.</given-names></name>
<name><surname>Leibner</surname><given-names>E.S.</given-names></name>
<name><surname>Hackett</surname><given-names>A.</given-names></name>
<name><surname>Maguire</surname><given-names>K.</given-names></name>
<name><surname>Mashriqi</surname><given-names>N.</given-names></name>
<name><surname>Kohli-Seth</surname><given-names>R.</given-names></name>
</person-group><article-title>The Third Wave: Comparing Seasonal Trends in COVID-19 Patient Data at a Large Hospital System in New York City</article-title><source>Crit. Care Explor.</source><year>2022</year><volume>4</volume><fpage>e0653</fpage><pub-id pub-id-type="doi">10.1097/CCE.0000000000000653</pub-id><pub-id pub-id-type="pmid">35261982</pub-id>
</element-citation>
      </ref>
      <ref id="B10-vaccines-12-00072">
        <label>10.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brosh-Nissimov</surname><given-names>T.</given-names></name>
<name><surname>Orenbuch-Harroch</surname><given-names>E.</given-names></name>
<name><surname>Chowers</surname><given-names>M.</given-names></name>
<name><surname>Elbaz</surname><given-names>M.</given-names></name>
<name><surname>Nesher</surname><given-names>L.</given-names></name>
<name><surname>Stein</surname><given-names>M.</given-names></name>
<name><surname>Maor</surname><given-names>Y.</given-names></name>
<name><surname>Cohen</surname><given-names>R.</given-names></name>
<name><surname>Hussein</surname><given-names>K.</given-names></name>
<name><surname>Weinberger</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>BNT162b2 Vaccine Breakthrough: Clinical Characteristics of 152 Fully Vaccinated Hospitalized COVID-19 Patients in Israel</article-title><source>Clin. Microbiol. Infect.</source><year>2021</year><volume>27</volume><fpage>1652</fpage><lpage>1657</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2021.06.036</pub-id><pub-id pub-id-type="pmid">34245907</pub-id>
</element-citation>
      </ref>
      <ref id="B11-vaccines-12-00072">
        <label>11.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vassallo</surname><given-names>M.</given-names></name>
<name><surname>Clement</surname><given-names>N.</given-names></name>
<name><surname>Lotte</surname><given-names>L.</given-names></name>
<name><surname>Manni</surname><given-names>S.</given-names></name>
<name><surname>Sindt</surname><given-names>A.</given-names></name>
<name><surname>Bertrand</surname><given-names>P.M.</given-names></name>
<name><surname>Durant</surname><given-names>J.</given-names></name>
</person-group><article-title>Prevalence and Main Clinical Characteristics of Fully Vaccinated Patients Admitted to Hospital for Delta Variant COVID-19</article-title><source>Front. Med.</source><year>2022</year><volume>9</volume><fpage>809154</fpage><pub-id pub-id-type="doi">10.3389/fmed.2022.809154</pub-id><?supplied-pmid 35308544?><pub-id pub-id-type="pmid">35308544</pub-id>
</element-citation>
      </ref>
      <ref id="B12-vaccines-12-00072">
        <label>12.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rzymski</surname><given-names>P.</given-names></name>
<name><surname>Pazgan-Simon</surname><given-names>M.</given-names></name>
<name><surname>Simon</surname><given-names>K.</given-names></name>
<name><surname>Łapiński</surname><given-names>T.</given-names></name>
<name><surname>Zarębska-Michaluk</surname><given-names>D.</given-names></name>
<name><surname>Szczepańska</surname><given-names>B.</given-names></name>
<name><surname>Chojnicki</surname><given-names>M.</given-names></name>
<name><surname>Mozer-Lisewska</surname><given-names>I.</given-names></name>
<name><surname>Flisiak</surname><given-names>R.</given-names></name>
</person-group><article-title>Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>781</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9070781</pub-id><?supplied-pmid 34358197?><pub-id pub-id-type="pmid">34358197</pub-id>
</element-citation>
      </ref>
      <ref id="B13-vaccines-12-00072">
        <label>13.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abate</surname><given-names>S.M.</given-names></name>
<name><surname>Checkol</surname><given-names>Y.A.</given-names></name>
<name><surname>Mantefardo</surname><given-names>B.</given-names></name>
</person-group><article-title>Global Prevalence and Determinants of Mortality among Patients with COVID-19: A Systematic Review and Meta-Analysis</article-title><source>Ann. Med. Surg.</source><year>2021</year><volume>64</volume><fpage>102204</fpage><pub-id pub-id-type="doi">10.1016/j.amsu.2021.102204</pub-id><?supplied-pmid 33692899?><pub-id pub-id-type="pmid">33692899</pub-id>
</element-citation>
      </ref>
      <ref id="B14-vaccines-12-00072">
        <label>14.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gray</surname><given-names>W.K.</given-names></name>
<name><surname>Navaratnam</surname><given-names>A.V.</given-names></name>
<name><surname>Day</surname><given-names>J.</given-names></name>
<name><surname>Wendon</surname><given-names>J.</given-names></name>
<name><surname>Briggs</surname><given-names>T.W.R.</given-names></name>
</person-group><article-title>COVID-19 Hospital Activity and in-Hospital Mortality during the First and Second Waves of the Pandemic in England: An Observational Study</article-title><source>Thorax</source><year>2022</year><volume>77</volume><fpage>1113</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2021-218025</pub-id><?supplied-pmid 34819384?><pub-id pub-id-type="pmid">34819384</pub-id>
</element-citation>
      </ref>
      <ref id="B15-vaccines-12-00072">
        <label>15.</label>
        <element-citation publication-type="gov">
          <person-group person-group-type="author">
<collab>National Center for Health Statistics (NCHS)</collab>
<collab>Centers for Disease Control and Prevention (CDC)</collab>
</person-group>
          <article-title>Glossary, National Health Interview Survey</article-title>
          <comment>Available online: <ext-link xlink:href="https://www.cdc.gov/nchs/nhis/tobacco/tobacco_glossary.htm" ext-link-type="uri">https://www.cdc.gov/nchs/nhis/tobacco/tobacco_glossary.htm</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2023-11-01">(accessed on 1 November 2023)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B16-vaccines-12-00072">
        <label>16.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Romagnoli</surname><given-names>S.</given-names></name>
<name><surname>Peris</surname><given-names>A.</given-names></name>
<name><surname>De Gaudio</surname><given-names>A.R.</given-names></name>
<name><surname>Geppetti</surname><given-names>P.</given-names></name>
</person-group><article-title>SARS-CoV-2 and COVID-19: From the Bench to the Bedside</article-title><source>Physiol. Rev.</source><year>2020</year><volume>100</volume><fpage>1455</fpage><lpage>1466</lpage><pub-id pub-id-type="doi">10.1152/physrev.00020.2020</pub-id><?supplied-pmid 32496872?><pub-id pub-id-type="pmid">32496872</pub-id>
</element-citation>
      </ref>
      <ref id="B17-vaccines-12-00072">
        <label>17.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ku</surname><given-names>E.</given-names></name>
<name><surname>Amaral</surname><given-names>S.</given-names></name>
<name><surname>McCulloch</surname><given-names>C.E.</given-names></name>
<name><surname>Adey</surname><given-names>D.B.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Johansen</surname><given-names>K.L.</given-names></name>
</person-group><article-title>Comparison of 2021 CKD-EPI Equations for Estimating Racial Differences in Preemptive Waitlisting for Kidney Transplantation</article-title><source>Clin. J. Am. Soc. Nephrol.</source><year>2022</year><volume>17</volume><fpage>1515</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.2215/CJN.04850422</pub-id><?supplied-pmid 36122938?><pub-id pub-id-type="pmid">36122938</pub-id>
</element-citation>
      </ref>
      <ref id="B18-vaccines-12-00072">
        <label>18.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bahl</surname><given-names>A.</given-names></name>
<name><surname>Johnson</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>N.-W.</given-names></name>
</person-group><article-title>Timing of Corticosteroids Impacts Mortality in Hospitalized COVID-19 Patients</article-title><source>Intern. Emerg. Med.</source><year>2021</year><volume>16</volume><fpage>1593</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.1007/s11739-021-02655-6</pub-id><pub-id pub-id-type="pmid">33547620</pub-id>
</element-citation>
      </ref>
      <ref id="B19-vaccines-12-00072">
        <label>19.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guzman-Esquivel</surname><given-names>J.</given-names></name>
<name><surname>Diaz-Martinez</surname><given-names>J.</given-names></name>
<name><surname>Ortega-Ortiz</surname><given-names>G.J.</given-names></name>
<name><surname>Murillo-Zamora</surname><given-names>E.</given-names></name>
<name><surname>Melnikov</surname><given-names>V.</given-names></name>
<name><surname>Tejeda-Luna</surname><given-names>R.H.</given-names></name>
<name><surname>Cosio-Medina</surname><given-names>G.V.</given-names></name>
<name><surname>Llerenas-Aguirre</surname><given-names>I.K.</given-names></name>
<name><surname>Guzman-Solorzano</surname><given-names>A.J.</given-names></name>
<name><surname>Hernandez-Fuentes</surname><given-names>A.G.</given-names></name>
<etal/>
</person-group><article-title>Interactions between the Principal Risk Factors for Reduction of the EGFR in Unvaccinated COVID-19 Survivors: Normal Pre-COVID-19 EGFR, Not Having Diabetes and Being Hospitalized</article-title><source>Exp. Ther. Med.</source><year>2023</year><volume>26</volume><fpage>580</fpage><pub-id pub-id-type="doi">10.3892/etm.2023.12279</pub-id><pub-id pub-id-type="pmid">38023357</pub-id>
</element-citation>
      </ref>
      <ref id="B20-vaccines-12-00072">
        <label>20.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baum</surname><given-names>M.K.</given-names></name>
<name><surname>Tamargo</surname><given-names>J.A.</given-names></name>
<name><surname>Diaz-Martinez</surname><given-names>J.</given-names></name>
<name><surname>Delgado-Enciso</surname><given-names>I.</given-names></name>
<name><surname>Meade</surname><given-names>C.S.</given-names></name>
<name><surname>Kirk</surname><given-names>G.D.</given-names></name>
<name><surname>Mehta</surname><given-names>S.H.</given-names></name>
<name><surname>Moore</surname><given-names>R.</given-names></name>
<name><surname>Kipke</surname><given-names>M.D.</given-names></name>
<name><surname>Shoptaw</surname><given-names>S.J.</given-names></name>
<etal/>
</person-group><article-title>HIV, Psychological Resilience, and Substance Misuse during the COVID-19 Pandemic: A Multi-Cohort Study</article-title><source>Drug Alcohol Depend.</source><year>2022</year><volume>231</volume><fpage>109230</fpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.109230</pub-id><pub-id pub-id-type="pmid">34998257</pub-id>
</element-citation>
      </ref>
      <ref id="B21-vaccines-12-00072">
        <label>21.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jaffa</surname><given-names>M.A.</given-names></name>
<name><surname>Gebregziabher</surname><given-names>M.</given-names></name>
<name><surname>Luttrell</surname><given-names>D.K.</given-names></name>
<name><surname>Luttrell</surname><given-names>L.M.</given-names></name>
<name><surname>Jaffa</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Multivariate Generalized Linear Mixed Models with Random Intercepts to Analyze Cardiovascular Risk Markers in Type-1 Diabetic Patients</article-title><source>J. Appl. Stat.</source><year>2016</year><volume>43</volume><fpage>1447</fpage><lpage>1464</lpage><pub-id pub-id-type="doi">10.1080/02664763.2015.1103708</pub-id><pub-id pub-id-type="pmid">27829695</pub-id>
</element-citation>
      </ref>
      <ref id="B22-vaccines-12-00072">
        <label>22.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naimi</surname><given-names>A.I.</given-names></name>
<name><surname>Whitcomb</surname><given-names>B.W.</given-names></name>
</person-group><article-title>Estimating Risk Ratios and Risk Differences Using Regression</article-title><source>Am. J. Epidemiol.</source><year>2020</year><volume>189</volume><fpage>508</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1093/aje/kwaa044</pub-id><?supplied-pmid 32219364?><pub-id pub-id-type="pmid">32219364</pub-id>
</element-citation>
      </ref>
      <ref id="B23-vaccines-12-00072">
        <label>23.</label>
        <element-citation publication-type="gov">
          <person-group person-group-type="author">
<collab>Gobierno de Mexico</collab>
</person-group>
          <article-title>Política Nacional de Vacunación Contra El Virus SARS-CoV-2, Para La Prevención de La COVID-19 En Mexico</article-title>
          <comment>Available online: <ext-link xlink:href="https://coronavirus.gob.mx/wp-content/uploads/2021/04/28Abr2021_13h00_PNVx_COVID_19.pdf" ext-link-type="uri">https://coronavirus.gob.mx/wp-content/uploads/2021/04/28Abr2021_13h00_PNVx_COVID_19.pdf</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2023-09-30">(accessed on 30 September 2023)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B24-vaccines-12-00072">
        <label>24.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loza</surname><given-names>A.</given-names></name>
<name><surname>Wong-Chew</surname><given-names>R.M.</given-names></name>
<name><surname>Jiménez-Corona</surname><given-names>M.-E.</given-names></name>
<name><surname>Zárate</surname><given-names>S.</given-names></name>
<name><surname>López</surname><given-names>S.</given-names></name>
<name><surname>Ciria</surname><given-names>R.</given-names></name>
<name><surname>Palomares</surname><given-names>D.</given-names></name>
<name><surname>García-López</surname><given-names>R.</given-names></name>
<name><surname>Iša</surname><given-names>P.</given-names></name>
<name><surname>Taboada</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Two-Year Follow-up of the COVID-19 Pandemic in Mexico</article-title><source>Front. Public Health</source><year>2023</year><volume>10</volume><fpage>1050673</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2022.1050673</pub-id><?supplied-pmid 36711379?><pub-id pub-id-type="pmid">36711379</pub-id>
</element-citation>
      </ref>
      <ref id="B25-vaccines-12-00072">
        <label>25.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zárate</surname><given-names>S.</given-names></name>
<name><surname>Taboada</surname><given-names>B.</given-names></name>
<name><surname>Rosales-Rivera</surname><given-names>M.</given-names></name>
<name><surname>García-López</surname><given-names>R.</given-names></name>
<name><surname>Muñoz-Medina</surname><given-names>J.E.</given-names></name>
<name><surname>Sanchez-Flores</surname><given-names>A.</given-names></name>
<name><surname>Herrera-Estrella</surname><given-names>A.</given-names></name>
<name><surname>Gómez-Gil</surname><given-names>B.</given-names></name>
<name><surname>Selem Mojica</surname><given-names>N.</given-names></name>
<name><surname>Salas-Lais</surname><given-names>A.G.</given-names></name>
<etal/>
</person-group><article-title>Omicron-BA.1 Dispersion Rates in Mexico Varied According to the Regional Epidemic Patterns and the Diversity of Local Delta Subvariants</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>243</elocation-id><pub-id pub-id-type="doi">10.3390/v15010243</pub-id><?supplied-pmid 36680283?><pub-id pub-id-type="pmid">36680283</pub-id>
</element-citation>
      </ref>
      <ref id="B26-vaccines-12-00072">
        <label>26.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
<name><surname>Ulises Pérez-Arenas</surname><given-names>L.</given-names></name>
<name><surname>Paola Plascencia-Roldán</surname><given-names>J.</given-names></name>
<name><surname>Irazú Morales-Reyes</surname><given-names>G.</given-names></name>
<name><surname>Flores-Vargas</surname><given-names>G.</given-names></name>
<name><surname>de Jesús Gallardo-Luna</surname><given-names>M.</given-names></name>
<name><surname>Navarro-Olivos</surname><given-names>E.</given-names></name>
<name><surname>Javier Magos-Vázquez</surname><given-names>F.</given-names></name>
<name><surname>Padilla-Raygoza</surname><given-names>N.</given-names></name>
</person-group>
          <article-title>Variants of SARS-CoV-2 and COVID-19 in Mexico</article-title>
          <source>New COVID-19 Variants [Working Title]</source>
          <publisher-name>IntechOpen</publisher-name>
          <publisher-loc>Rijeka, Croatia</publisher-loc>
          <year>2023</year>
        </element-citation>
      </ref>
      <ref id="B27-vaccines-12-00072">
        <label>27.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farrell</surname><given-names>J.M.</given-names></name>
<name><surname>Zhao</surname><given-names>C.Y.</given-names></name>
<name><surname>Tarquinio</surname><given-names>K.M.</given-names></name>
<name><surname>Brown</surname><given-names>S.P.</given-names></name>
</person-group><article-title>Causes and Consequences of COVID-19-Associated Bacterial Infections</article-title><source>Front. Microbiol.</source><year>2021</year><volume>12</volume><elocation-id>682571</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2021.682571</pub-id><?supplied-pmid 34354682?><pub-id pub-id-type="pmid">34354682</pub-id>
</element-citation>
      </ref>
      <ref id="B28-vaccines-12-00072">
        <label>28.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>G.</given-names></name>
<name><surname>Lu</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>He</surname><given-names>Y.</given-names></name>
</person-group><article-title>Characteristics and Risk Factors of Secondary Bacterial Infections in COVID-19 Patients</article-title><source>Antimicrob. Steward. Healthc. Epidemiol.</source><year>2023</year><volume>3</volume><fpage>e156</fpage><pub-id pub-id-type="doi">10.1017/ash.2023.425</pub-id><?supplied-pmid 37771749?><pub-id pub-id-type="pmid">37771749</pub-id>
</element-citation>
      </ref>
      <ref id="B29-vaccines-12-00072">
        <label>29.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dietz</surname><given-names>L.L.</given-names></name>
<name><surname>Juhl</surname><given-names>A.K.</given-names></name>
<name><surname>Søgaard</surname><given-names>O.S.</given-names></name>
<name><surname>Reekie</surname><given-names>J.</given-names></name>
<name><surname>Nielsen</surname><given-names>H.</given-names></name>
<name><surname>Johansen</surname><given-names>I.S.</given-names></name>
<name><surname>Benfield</surname><given-names>T.</given-names></name>
<name><surname>Wiese</surname><given-names>L.</given-names></name>
<name><surname>Stærke</surname><given-names>N.B.</given-names></name>
<name><surname>Jensen</surname><given-names>T.Ø.</given-names></name>
<etal/>
</person-group><article-title>Impact of Age and Comorbidities on SARS-CoV-2 Vaccine-Induced T Cell Immunity</article-title><source>Commun. Med.</source><year>2023</year><volume>3</volume><fpage>58</fpage><pub-id pub-id-type="doi">10.1038/s43856-023-00277-x</pub-id><?supplied-pmid 37095240?><pub-id pub-id-type="pmid">37095240</pub-id>
</element-citation>
      </ref>
      <ref id="B30-vaccines-12-00072">
        <label>30.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Montes-Galindo</surname><given-names>D.A.</given-names></name>
<name><surname>Espiritu-Mojarro</surname><given-names>A.C.</given-names></name>
<name><surname>Melnikov</surname><given-names>V.</given-names></name>
<name><surname>Moy-López</surname><given-names>N.A.</given-names></name>
<name><surname>Soriano-Hernandez</surname><given-names>A.D.</given-names></name>
<name><surname>Galvan-Salazar</surname><given-names>H.R.</given-names></name>
<name><surname>Guzman-Muñiz</surname><given-names>J.</given-names></name>
<name><surname>Guzman-Esquivel</surname><given-names>J.</given-names></name>
<name><surname>Martinez-Fierro</surname><given-names>M.L.</given-names></name>
<name><surname>Rodriguez-Sanchez</surname><given-names>I.P.</given-names></name>
<etal/>
</person-group><article-title>Adenovirus 5 Produces Obesity and Adverse Metabolic, Morphological, and Functional Changes in the Long Term in Animals Fed a Balanced Diet or a High-Fat Diet: A Study on Hamsters</article-title><source>Arch. Virol.</source><year>2019</year><volume>164</volume><fpage>775</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1007/s00705-018-04132-6</pub-id><?supplied-pmid 30666458?><pub-id pub-id-type="pmid">30666458</pub-id>
</element-citation>
      </ref>
      <ref id="B31-vaccines-12-00072">
        <label>31.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Voss</surname><given-names>J.D.</given-names></name>
<name><surname>Atkinson</surname><given-names>R.L.</given-names></name>
<name><surname>Dhurandhar</surname><given-names>N.V.</given-names></name>
</person-group><article-title>Role of Adenoviruses in Obesity</article-title><source>Rev. Med. Virol.</source><year>2015</year><volume>25</volume><fpage>379</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1002/rmv.1852</pub-id><pub-id pub-id-type="pmid">26352001</pub-id>
</element-citation>
      </ref>
      <ref id="B32-vaccines-12-00072">
        <label>32.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Banoun</surname><given-names>H.</given-names></name>
</person-group><article-title>MRNA: Vaccine or Gene Therapy? The Safety Regulatory Issues</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>10514</elocation-id><pub-id pub-id-type="doi">10.3390/ijms241310514</pub-id><pub-id pub-id-type="pmid">37445690</pub-id>
</element-citation>
      </ref>
      <ref id="B33-vaccines-12-00072">
        <label>33.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zsengellér</surname><given-names>Z.K.</given-names></name>
<name><surname>Wert</surname><given-names>S.E.</given-names></name>
<name><surname>Bachurski</surname><given-names>C.J.</given-names></name>
<name><surname>Kirwin</surname><given-names>K.L.</given-names></name>
<name><surname>Trapnell</surname><given-names>B.C.</given-names></name>
<name><surname>Whitsett</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Recombinant Adenoviral Vector Disrupts Surfactant Homeostasis in Mouse Lung</article-title><source>Hum. Gene Ther.</source><year>1997</year><volume>8</volume><fpage>1331</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.1089/hum.1997.8.11-1331</pub-id><pub-id pub-id-type="pmid">9295128</pub-id>
</element-citation>
      </ref>
      <ref id="B34-vaccines-12-00072">
        <label>34.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsilingiris</surname><given-names>D.</given-names></name>
<name><surname>Vallianou</surname><given-names>N.G.</given-names></name>
<name><surname>Karampela</surname><given-names>I.</given-names></name>
<name><surname>Muscogiuri</surname><given-names>G.</given-names></name>
<name><surname>Dalamaga</surname><given-names>M.</given-names></name>
</person-group><article-title>Use of Adenovirus Type-5 Vector Vaccines in COVID-19: Potential Implications for Metabolic Health?</article-title><source>Minerva Endocrinol.</source><year>2022</year><volume>47</volume><fpage>264</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.23736/S2724-6507.22.03797-6</pub-id><?supplied-pmid 35621112?><pub-id pub-id-type="pmid">35621112</pub-id>
</element-citation>
      </ref>
      <ref id="B35-vaccines-12-00072">
        <label>35.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Flotte</surname><given-names>T.R.</given-names></name>
<name><surname>Gao</surname><given-names>G.</given-names></name>
</person-group><article-title>Immune Responses to Recombinant Adenoviruses As Gene Therapy Vectors and COVID-19 Vaccines: A Two-Edged Sword</article-title><source>Hum. Gene Ther.</source><year>2021</year><volume>32</volume><fpage>645</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1089/hum.2021.29169.trf</pub-id><?supplied-pmid 34283643?><pub-id pub-id-type="pmid">34283643</pub-id>
</element-citation>
      </ref>
      <ref id="B36-vaccines-12-00072">
        <label>36.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosero-Bixby</surname><given-names>L.</given-names></name>
</person-group><article-title>The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence</article-title><source>JMIR Public Health Surveill.</source><year>2022</year><volume>8</volume><fpage>e35054</fpage><pub-id pub-id-type="doi">10.2196/35054</pub-id><?supplied-pmid 35483079?><pub-id pub-id-type="pmid">35483079</pub-id>
</element-citation>
      </ref>
      <ref id="B37-vaccines-12-00072">
        <label>37.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lopez Bernal</surname><given-names>J.</given-names></name>
<name><surname>Andrews</surname><given-names>N.</given-names></name>
<name><surname>Gower</surname><given-names>C.</given-names></name>
<name><surname>Robertson</surname><given-names>C.</given-names></name>
<name><surname>Stowe</surname><given-names>J.</given-names></name>
<name><surname>Tessier</surname><given-names>E.</given-names></name>
<name><surname>Simmons</surname><given-names>R.</given-names></name>
<name><surname>Cottrell</surname><given-names>S.</given-names></name>
<name><surname>Roberts</surname><given-names>R.</given-names></name>
<name><surname>O’Doherty</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca Vaccines on COVID-19 Related Symptoms, Hospital Admissions, and Mortality in Older Adults in England: Test Negative Case-Control Study</article-title><source>BMJ</source><year>2021</year><volume>373</volume><fpage>n1088</fpage><pub-id pub-id-type="doi">10.1136/bmj.n1088</pub-id><pub-id pub-id-type="pmid">33985964</pub-id>
</element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig position="float" id="vaccines-12-00072-f001">
      <label>Figure 1</label>
      <caption>
        <p>Flowchart depicting the selection process from a total of 1747 hospitalized individuals according to inclusion and exclusion criteria.</p>
      </caption>
      <graphic xlink:href="vaccines-12-00072-g001" position="float"/>
    </fig>
    <fig position="float" id="vaccines-12-00072-f002">
      <label>Figure 2</label>
      <caption>
        <p>Pneumonia Severity Index of patients with different vaccination schemes according to the pandemic period. It is observed that vaccinated patients show variations in severity depending on the pandemic period, while the severity of the non-vaccinated remained constant. In the period when the Delta variant was predominant, vaccinated patients experienced higher severity than the non-vaccinated, exhibiting the opposite trend in other periods. Periods were established based on the predominant variants in the general population of Mexico ([<xref rid="B24-vaccines-12-00072" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-12-00072" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-00072" ref-type="bibr">26</xref>]; January–July 2021: B.1.1.222; B.1.1.519; and Gamma. August–December 2021: Delta. January–April 2022: Delta, Omicron BA.1; Omicron BA.1.1, Omicron BA.1.15. May–December 2022: Omicron, others. * <italic toggle="yes">p</italic> &lt; 0.01. Mean + 95% CI is shown.</p>
      </caption>
      <graphic xlink:href="vaccines-12-00072-g002" position="float"/>
    </fig>
    <fig position="float" id="vaccines-12-00072-f003">
      <label>Figure 3</label>
      <caption>
        <p>Kaplan-Meier curves for 40 days based on vaccination scheme. (<bold>A</bold>) Overall, BNT162b2-vaccinated patients show better survival than the other groups (multiple comparisons <italic toggle="yes">p</italic> = 0.003. Post-hoc analysis: <italic toggle="yes">p</italic> = BNT162b2 vs. unvaccinated <italic toggle="yes">p</italic> = 0.001. ChAdOx1-S vs. unvaccinated <italic toggle="yes">p</italic> = 0.130. BNT162b2 vs. ChAdOx1-S <italic toggle="yes">p</italic> = 0.223). (<bold>B</bold>) Among those hospitalized in advanced stages (pulmonary and hyperinflammatory phase), a similar trend is observed (multiple comparisons <italic toggle="yes">p</italic> = 0.036. Post-hoc analysis: BNT162b2 vs. unvaccinated <italic toggle="yes">p</italic> = 0.076. ChAdOx1-S vs. unvaccinated <italic toggle="yes">p</italic> = 0.120. BNT162b2 vs. ChAdOx1-S <italic toggle="yes">p</italic> = 0.014. (<bold>C</bold>) In patients hospitalized in an early stage (viral phase), no significant differences were found between the groups (multiple comparisons <italic toggle="yes">p</italic> = 0.124). (<bold>D</bold>) In patients hospitalized with PSI values &lt; 120, BNT162b2-vaccinated individuals had higher survival (multiple comparisons <italic toggle="yes">p</italic> = 0.001. Post-hoc analysis: BNT162b2 vs. unvaccinated <italic toggle="yes">p</italic> = 0.002. ChAdOx1-S vs. unvaccinated <italic toggle="yes">p</italic> = 0.161. BNT162b2 vs. ChAdOx1-S <italic toggle="yes">p</italic> = 0.137). (<bold>E</bold>) When having a PSI &gt; 120 at hospital admission, the groups did not differ (multiple comparisons <italic toggle="yes">p</italic> = 0.395). (<bold>F</bold>) Among patients aged 60 years or older, BNT162b2-vaccinated individuals had higher survival than the other groups (multiple comparisons <italic toggle="yes">p</italic> &lt; 0.001. Post-hoc analysis: BNT162b2 vs. unvaccinated <italic toggle="yes">p</italic> = 0.002. ChAdOx1-S vs. unvaccinated <italic toggle="yes">p</italic> = 0.161. BNT162b2 vs. ChAdOx1-S <italic toggle="yes">p</italic> = 0.137), while in those under 60 years, no differences were found between the groups (multiple comparisons <italic toggle="yes">p</italic> = 0.386). The log-rank test was applied to compare curves in multiple comparisons or post-hoc analysis.</p>
      </caption>
      <graphic xlink:href="vaccines-12-00072-g003" position="float"/>
    </fig>
    <fig position="float" id="vaccines-12-00072-f004">
      <label>Figure 4</label>
      <caption>
        <p>Evolution of some clinical parameters during the first 6 days of hospitalization for patients based on the type of vaccine received. It is observed that the National Early Warning Score 2 (NEWS-2) is lower in the vaccinated groups compared to the non-vaccinated group (<bold>A</bold>). In contrast, regarding the Pneumonia Severity Index (PSI), BNT162b2-vaccinated individuals show higher severity (<bold>B</bold>). However, it is noticeable that both ChAdOx1-S-vaccinated individuals (in (<bold>A</bold>,<bold>B</bold>)) and the non-vaccinated group experience an increase over the course of days (<bold>B</bold>). The lymphocyte count (<bold>C</bold>) is higher in vaccinated individuals, with a markedly lower platelet-to-lymphocyte ratio (<bold>D</bold>) in these groups compared to the non-vaccinated group. Ferritin levels (<bold>E</bold>) are lower in BNT162b2-vaccinated individuals compared to those vaccinated with ChAdOx1-S and the non-vaccinated group. Average values and 95% confidence intervals are presented.</p>
      </caption>
      <graphic xlink:href="vaccines-12-00072-g004" position="float"/>
    </fig>
    <table-wrap position="float" id="vaccines-12-00072-t001">
      <object-id pub-id-type="pii">vaccines-12-00072-t001_Table 1</object-id>
      <label>Table 1</label>
      <caption>
        <p>Data on the COVID vaccination scheme in hospitalized patients.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Clinical <break/>Characteristic</th>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
            <th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">Vaccinated</th>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
          </tr>
          <tr>
            <th align="center" valign="middle" rowspan="1" colspan="1">All</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">No</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Yes</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th>
          </tr>
          <tr>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n = 514</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n = 288</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n = 226</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="5" align="center" valign="middle" rowspan="1">Medical personal history</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Age (years)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">63.3 ± 16.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">62.2 ± 16.3</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">64.6 ± 15.7</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.084 *</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">≥60 years</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">63.1%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">57.1%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">70.8%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.001 **</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Male (%)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">61.9%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">61.5%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">62.4%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.451 **</td>
          </tr>
          <tr>
            <td colspan="5" align="center" valign="middle" rowspan="1">Data on the COVID vaccination scheme</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Vaccinated</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">56.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">44.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">ChAdOx1-S <sup>a</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">17.9%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">BNT162b2 <sup>b</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">21.7%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Ad5-nCoV</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.7%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">CorovaVac <sup>c</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.7%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td colspan="2" align="center" valign="middle" rowspan="1">Complete primary series</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">38.2%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Booster vaccinations <sup>d</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">8.9%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Days since last application</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132.9 ± 97.0</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>Percentages or averages and standard deviation are shown. * Independent Student’s <italic toggle="yes">t</italic>-test analysis. ** Fisher’s exact tests. <sup>a</sup> Oxford—AstraZeneca. <sup>b</sup> Pfizer—BioNTech. <sup>c</sup> Sinovac. <sup>d</sup> Only ChAdOx1-S (Oxford–AstraZeneca) was used.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap position="float" id="vaccines-12-00072-t002">
      <object-id pub-id-type="pii">vaccines-12-00072-t002_Table 2</object-id>
      <label>Table 2</label>
      <caption>
        <p>Main clinical characteristics of the participating subjects at the time of enrollment and prescribed drugs.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Clinical </th>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
            <th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">Vaccinated</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> *</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
          </tr>
          <tr>
            <th align="left" valign="middle" rowspan="1" colspan="1">Characteristic</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">No</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">ChAdOx1-S</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">BNT162b2</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Inter-</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">No vs.</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">No vs. </th>
            <th align="center" valign="middle" rowspan="1" colspan="1">ChAdOx1-S </th>
          </tr>
          <tr>
            <th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n = 288 <break/>(100%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n = 73 (100%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n = 101 (100%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Group</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChAdOx1-S </th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">vs. BNT162b2</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">≥60 years</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">57.1%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">57.5%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">90.1%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.527</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Male (%)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">61.5%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">61.6%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">65.3%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.777</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Diabetes </td>
            <td align="center" valign="middle" rowspan="1" colspan="1">38.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">54.8%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">50.5%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.009 *</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.007</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.019</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.342</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">HBP </td>
            <td align="center" valign="middle" rowspan="1" colspan="1">34.3%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">56.2%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">54.5%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001 *</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.473</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">BMI</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">30.4 ± 7.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">29.3 ± 4.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">30.6 ± 7.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.264</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Smoking</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">9.6%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.4%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.1%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.025 *</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.013</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.197</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.135</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">CKD</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">16.3%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">40.3%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">29.7%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.003</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.100</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Charlson Index</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.2 ± 2.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.2 ± 2.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.7 ± 1.7</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001 *</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.106</td>
          </tr>
          <tr>
            <td colspan="5" align="left" valign="middle" rowspan="1">Clinical data at hospital admission</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">PSI </td>
            <td align="center" valign="middle" rowspan="1" colspan="1">107 ± 42</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">106 ± 37</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">117 ± 36</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.110</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Disease phase</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.058</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">  Viral</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">27.7%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">60.3%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">45.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">  Pulmonary</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">57.1%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">28.8%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">30.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">  Inflammation</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">15.2%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">11.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">25.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">C-GRAM</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">135 ± 36</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">131 ± 41</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">134 ± 32</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.692</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">NEWS-2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.7 ± 3.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.5 ± 3.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.6 ± 3.0</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.003</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.011</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.007</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.843</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Neutrophils</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7309 ± 5972</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">10,604 ± 7244</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">9606 ± 6101</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.336</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Lymphocytes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">801 ± 793</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1094 ± 714</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1023 ± 789</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.004</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.005</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.019</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.554</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">PlateletsX1000</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">261 ± 122</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">267 ± 147</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">244 ± 103</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.390</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">NLR</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">13.0 ± 12.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">15.3 ± 21.6</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">13.6 ± 12.9</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.487</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">D-Dimer </td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2999 ± 2184</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3142 ± 5579</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2180 ± 3583</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.914</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">ESR </td>
            <td align="center" valign="middle" rowspan="1" colspan="1">29.8 ± 11.6</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">34.5 ± 16.8</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">23.8 ± 11.7</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.050</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.226</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.047</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0. 045</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">CRP </td>
            <td align="center" valign="middle" rowspan="1" colspan="1">17.1 ± 18.6</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">15.5 ± 11.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">16.6 ± 28.8</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.971 *</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Ferritin</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">845.8 ± 638.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">655.2 ± 586.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">559.7 ± 336.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.017</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.122</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.009</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.394</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Creatinine</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.2 ± 3.7</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.8 ± 4.4</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.4 ± 3.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.006</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.003</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.760</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.014</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">eGFR</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">73.9 ± 48.7</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">51.9 ± 58.3</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">54.1 ± 36.7</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.003</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.002</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.999</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">AST</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">50.1 ± 51.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">125.6 ± 397.6</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">67.5 ± 193.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.046</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.007</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.328</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.329</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">ALT</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">41.2 ± 38.8</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">83.2 ± 216.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">42.4 + 122.8</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.035</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.008</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.900</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.195</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">ALP</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">99.3 ± 65.6</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">139.8 ± 170.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">103.1 ± 70.8</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.068</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">LDH</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">384.2 ± 209.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">502.4 ± 954.6</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">345.8 ± 288.0</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.078</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Glucose</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">191.5 ± 132.3</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">179.5 ± 129.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">214.9 ± 169.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.232</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">INR</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.14 + 0.25</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.13 + 0.31</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.19 + 0.59</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.690</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td colspan="8" align="left" valign="middle" rowspan="1">Main treatments during hospital stay</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">AKI</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">16.7%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">35.6%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">18.7%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.002</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.545</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.004</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Paracetamol</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">11.4%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">11.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.054</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Anticoagulants</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">89.3%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">86.3%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">94.1%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.193</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Antibiotics</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">48.7%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">42.3%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">49.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.746</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Amine support</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">9.7%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.8%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">8.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.689</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Steroids</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">90.6%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">93.2%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">93.1%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.642</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Diuretics</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">14.6%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">29.5%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">22.1%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.150</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Mech. Vent.</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">38.1%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">23.3%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">21.8%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.002</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.012</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.002</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.478</td>
          </tr>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemodialysis</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.0%</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.2%</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.0%</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.010</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.015</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.139</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>Percentages or averages and standard deviation are shown. * To compare three groups (intergroup analysis), ANOVA or likelihood ratio chi-square test was performed, to compare two groups, independent Student’s <italic toggle="yes">t</italic>-test or Fisher’s exact test was used, as appropriate for numerical or qualitative data, respectively. BMI: Body mass index. HBP: Systemic arterial hypertension. Smoking: current smoker. CKD: Chronic kidney disease. PSI: Pneumonia Severity Index. C-GRAM: Critical Illness Risk Score (COVID-GRAM). NEWS-2: National Early Warning Score 2. Neutrophils, lymphocytes, and plateletsX1000, expressed in cells per microliter of blood. NLR: neutrophil/lymphocyte ratio: D-Dimer expressed in ng/mL. ESR: Erythrocyte Sedimentation Rate, mm/hour. CRP: C-Reactive Protein mg/dL. Ferritin expressed in ng/mL. Creatinine expressed in mg/dL. eGFR: estimated glomerular filtration rate, expressed in mL/min/1.73 m<sup>2</sup>. ALP: alkaline phosphatase, expressed in international units per liter (IU/L). AST: aspartate amino transferase, expressed in IU/L. ALT: alanine aminotransferase, expressed in IU/L. LDH: Lactate Dehydrogenase expressed in IU/L. Glucose expressed in mg/dL. INR: prothrombin time expressed as an international normalized ratio. AKI: Acute kidney injury. Mech. Vent.: Mechanical ventilation.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap position="float" id="vaccines-12-00072-t003">
      <object-id pub-id-type="pii">vaccines-12-00072-t003_Table 3</object-id>
      <label>Table 3</label>
      <caption>
        <p>Main clinical data throughout the hospital stay and prescribed drugs.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Clinical </th>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
            <th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">Vaccinated</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> *</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
          </tr>
          <tr>
            <th align="left" valign="middle" rowspan="1" colspan="1">Characteristic</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">No</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">ChAdOx1-S </th>
            <th align="center" valign="middle" rowspan="1" colspan="1">BNT162b2</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Inter-</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">No vs.</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">No vs. </th>
            <th align="center" valign="middle" rowspan="1" colspan="1">ChAdOx1-S </th>
          </tr>
          <tr>
            <th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n = 288</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n = 73</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n = 101 </th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Group</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChAdOx1-S </th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">vs. BNT162b2</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Days hosp.</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">   All</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">8.9 ± 6.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.6 ± 5.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">8.4 ± 6.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.207</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">   D. alive</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.6 ± 5.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.8 ± 4.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.9 ± 5.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.492</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">   D. dead</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">10.2 ± 6.6</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">8.8 ± 6.0</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">9.2 ± 8.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.533</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Deaths</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">52.6%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">41.1%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">31.7%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.052</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.132</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="middle" rowspan="1">Death according to age</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">   &lt;60 years</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">40.3%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">29.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">20.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.245</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">   ≥60 years</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">61.8%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">50.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">33.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.112</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.047</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="middle" rowspan="1">Deaths according to Disease phase at admission</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">   Viral</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">34.2%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">20.5%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">19.1%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.104</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">   Advanced **</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">59.8%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">72.4%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">43.4%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.024</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.134</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.023</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.010</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="middle" rowspan="1">Deaths according to PSI at admission</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">   PSI score &lt; 120</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">32.2%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">21.7%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">11.1%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.002</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.115</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.107</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">   PSI score ≥ 120</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">85.8%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">76.0%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">67.6%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.046</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.180</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.016</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.336</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Death with booster vaccination</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.1%</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.4%</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.414</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>Percentages or averages and standard deviation are shown. * To compare three groups (intergroup analysis), ANOVA or likelihood ratio chi-square test was performed, to compare two groups, independent Student’s <italic toggle="yes">t</italic>-test or Fisher’s exact test was used, as appropriate for numerical or qualitative data, respectively. Days hosp.: Days of hospital stay. D. alive, and D. dead: Days of hospital stay in patients who lived and in patients who died, respectively. ** Advanced disease phase at admission: Pulmonary and hyper-inflammatory phases. PSI: Pneumonia Severity Index.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap position="float" id="vaccines-12-00072-t004">
      <object-id pub-id-type="pii">vaccines-12-00072-t004_Table 4</object-id>
      <label>Table 4</label>
      <caption>
        <p>Relative risk from multivariate generalized linear mixed model with binary logistic regression link of various clinical characteristics and vaccination schedule to have a fatal outcome in patients hospitalized for COVID-19.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
            <th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">95% CI</th>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
          </tr>
          <tr>
            <th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Covariate</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad RR</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lower</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Upper</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Age ≥ 60 years</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.46</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.91</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.37</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.119</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Male</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.97</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.63</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.50</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.887</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Diabetes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.18</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.76</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.82</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.471</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">HBP</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.83</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.53</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.29</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.405</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Smoking</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.50</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.00</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">10.14</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">CKD</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.42</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.72</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.83</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.314</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Charlson Index</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.67</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.60</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">11.97</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.199</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Admission phase</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.01</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.47</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.50</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">NEWS-2 score ≥ 12</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.56</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.64</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.76</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.001</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">PSI score &gt; 120</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">8.14</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">5.06</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">13.09</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Mech. Vent.</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.74</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.89</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.39</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Creatinine ≥ 4mg/dL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.89</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.39</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.04</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.777</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">AKI</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.10</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.63</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.92</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.726</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Hemodialysis</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.70</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.16</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.09</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.633</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Neutrophils ≥ 8 × 10e<sup>3</sup>/uL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.76</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.34</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.02</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Lymphocytes ≥ 680/uL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.53</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.34</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.84</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.007</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">AST ≥ 50UL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.40</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.81</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.42</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.229</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">ALT ≥ 45UL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.45</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.26</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.79</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.005</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Ferritin ≥ 810 ng/mL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.91</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.58</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.42</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.668</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">ESR ≥ 30 mm/h</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.42</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.66</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.05</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.370</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Vaccine type</bold>
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">BNT162b2/ChAdOx1-S 2 doses α</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.54</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.30</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.97</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.041 </td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">   BNT162b2 2 doses α </td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.41</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.22</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.79</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.008</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">   ChAdOx1-S 2 doses α</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.04</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.48</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.29</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.915</td>
          </tr>
          <tr>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">   Booster vaccination Ω</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.74</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.68</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.45</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.247</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>The multivariate statistical model included all the listed characteristics (fixed effects), which were considered as risk factors for mortality, their absence being classified as the reference, except for the type of vaccine administered, where the reference was the unvaccinated. Adjustment is for all variables listed, including vaccine type classified as; No, BNT162b2 (two doses), or ChAdOx1-S (two doses). The month of hospitalization (pandemic period) was included in the model as a random effect. HBP: Systemic arterial hypertension. Smoking: current smoker. CKD: Chronic kidney disease. Admission phase: Advanced disease phase at admission (Pulmonary and hyper-inflammatory phases, reference: viral phase). NEWS-2: National Early Warning Score 2. PSI: Pneumonia Severity Index. Mech. Vent.: Mechanical ventilation. AKI: Acute kidney injury. AST: aspartate amino transferase, expressed in international units per liter (IU/L). ALT: alanine aminotransferase, expressed in IU/L. ESR: Erythrocyte Sedimentation Rate, mm/hour. ChAdOx1-S: Oxford–AstraZeneca. BNT162b2: Pfizer–BioNTech. α In comparison with not vaccinated group. Ω Booster vaccination: only ChAdOx1-S (Oxford–AstraZeneca) was used. The dichotomization of variables was determined through an analysis with the area under the receiver operating characteristic (ROC) curve, with its respective cut-off point, calculated to discriminate subjects who died.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap position="float" id="vaccines-12-00072-t005">
      <object-id pub-id-type="pii">vaccines-12-00072-t005_Table 5</object-id>
      <label>Table 5</label>
      <caption>
        <p>Relative risk from multivariate generalized linear mixed model with binary logistic regression link, comparing various clinical characteristics and the BNT162b2 vaccination schedule with ChAdOx1-S in patients hospitalized for COVID-19.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
            <th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">95% CI</th>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
          </tr>
          <tr>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Covariate</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad RR</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lower</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Upper</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Age ≥ 60 years</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.61</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.74</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">21.11</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Male</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.42</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.62</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.24</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.407</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Smoking</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.88</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.20</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.88</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.861</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">CKD</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.75</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.28</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.00</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.570</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Charlson Index</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.07</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.82</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.39</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.633</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Admission phase</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.30</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.14</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.63</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.020</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">NEWS-2 score ≥ 12</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.84</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.55</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.20</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.322</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">PSI score ≥ 120</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.91</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.50</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">10.22</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.006</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Mech. Vent.</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.24</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.41</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.78</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.701</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Creatinine ≥ 4mg/dL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.58</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.17</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.00</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.389</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">AKI</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.88</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.37</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.06</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.762</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Neutrophils ≥ 8 × 10e<sup>3</sup>/uL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.87</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.37</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.05</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.753</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Lymphocytes ≥ 680/uL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.95</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.44</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.03</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.893</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">AST ≥ 50UL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.42</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.61</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.30</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.410</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">ALT ≥ 45UL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.46</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.17</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.24</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.123</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Ferritin ≥ 810 ng/mL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.21</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.09</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.46</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">ESR ≥ 30 mm/h</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.91</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.58</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.42</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.668</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Booster vaccination Ω</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.32</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.13</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.75</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.009</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.27</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.10</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.70</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>The multivariate statistical model included and adjusted for all the listed characteristics (introduced into the model as fixed effects). The month of hospitalization (pandemic period) was included in the model as a random effect. Smoking: current smoker. CKD: Chronic kidney disease. Admission phase: advanced disease phase at admission (pulmonary and hyper-inflammatory phases, reference: viral phase). NEWS-2: National Early Warning Score 2. PSI: Pneumonia Severity Index. Mech. Vent.: Mechanical ventilation. AKI: Acute kidney injury. AST: aspartate amino transferase, expressed in international units per liter (IU/L). ALT: alanine aminotransferase, expressed in IU/L. ESR: Erythrocyte Sedimentation Rate, mm/hour. ChAdOx1-S: Oxford–AstraZeneca. BNT162b2: BNT162b2–BioNTech. Ω Booster vaccination: only ChAdOx1-S (Oxford–AstraZeneca) was used. The dichotomization of variables was determined through an analysis with the area under the receiver operating characteristic (ROC) curve, with its respective cut-off point, calculated to discriminate subjects who died.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap position="float" id="vaccines-12-00072-t006">
      <object-id pub-id-type="pii">vaccines-12-00072-t006_Table 6</object-id>
      <label>Table 6</label>
      <caption>
        <p>Relative risk from multivariate generalized linear mixed model with binary logistic regression link of various clinical characteristics and BNT162b2 vaccination schedule in comparison with non-vaccinated individuals in patients hospitalized for COVID-19.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
            <th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">95% CI</th>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
          </tr>
          <tr>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Covariate</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad RR</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lower</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Upper</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Age ≥ 60 years</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.25</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.70</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.22</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.000</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Male</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.78</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.10</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.88</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.018</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Smoking</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.38</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.15</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.94</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.037</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">CKD</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.69</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.35</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.37</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.297</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Charlson Index</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.41</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.20</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.65</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.000</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Admission phase</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.88</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.55</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.42</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.622</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">NEWS-2 score ≥ 12</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.18</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.62</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.26</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.603</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">PSI score ≥ 120</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.50</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.82</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.74</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.186</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Mech. Vent.</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.13</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.60</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.12</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.686</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Creatinine ≥ 4mg/dL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.58</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.73</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.38</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.237</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">AKI</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.54</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.31</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.93</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.028</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Neutrophils ≥ 8 × 10e<sup>3</sup>/uL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.43</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.51</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.89</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.000</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Lymphocytes ≥ 680/uL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.63</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.34</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">5.62</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.000</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">AST ≥ 50UL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.02</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.59</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.78</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.919</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">ALT ≥ 45UL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.64</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.35</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.19</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.163</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Ferritin ≥ 810 ng/mL</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.74</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.46</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.19</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.220</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">ESR ≥ 30 mm/h</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.03</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.47</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.22</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.939</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.38</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.19</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.72</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.004</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>The multivariate statistical model included and adjusted for all the listed characteristics (introduced into the model as fixed effects). The month of hospitalization (pandemic period) was included in the model as a random effect. Smoking: current smoker. CKD: Chronic kidney disease. Admission phase: advanced disease phase at admission (pulmonary and hyper-inflammatory phases, reference: viral phase). NEWS-2: National Early Warning Score 2. PSI: Pneumonia Severity Index. Mech. Vent.: Mechanical ventilation. AKI: Acute kidney injury. AST: aspartate amino transferase, expressed in international units per liter (IU/L). ALT: alanine aminotransferase, expressed in IU/L. ESR: Erythrocyte Sedimentation Rate, mm/hour. ChAdOx1-S: Oxford–AstraZeneca. BNT162b2: Pfizer–BioNTech. Ω Booster vaccination: only ChAdOx1-S (Oxford–AstraZeneca) was used. The dichotomization of variables was determined through an analysis with the area under the receiver operating characteristic (ROC) curve, with its respective cut-off point, calculated to discriminate subjects who died.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap position="float" id="vaccines-12-00072-t007">
      <object-id pub-id-type="pii">vaccines-12-00072-t007_Table 7</object-id>
      <label>Table 7</label>
      <caption>
        <p>Mean and <italic toggle="yes">p</italic>-values resulting from the analysis of repeated measurements during the first 6 days of hospitalization of some clinical parameters using multivariate linear mixed effects models.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
            <th colspan="3" align="center" valign="middle" style="border-top:solid thin" rowspan="1">Mean, First 6 Days</th>
            <th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1"><italic toggle="yes">p</italic>-Value No vs.</th>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">ChAdOx1-S<break/>vs.</th>
          </tr>
          <tr>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No </th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChAdOx1-S </th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChAdOx1-S</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Ferritin</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1043 ± 758</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1031 ± 813</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">632 ± 473</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.646</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Lymphocytes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">740.7 ± 776</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1055 ± 699</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1008 ± 836</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.148</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">PLR</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1259 ± 2317</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">339 ± 301</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">423 ± 460</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.055</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">NEWS-2 </td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.8 ± 3.8</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.3 ± 3.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.1 ± 3.4</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.004</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.028</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.450</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PSI score</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110.5 ± 44</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110.6 ± 39</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">119.3 ± 38</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.302</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>Mean ± standard deviation of the values during the first 6 days of hospitalization. <italic toggle="yes">p</italic>-values obtained by univariate linear mixed effects model tests. ChAdOx1-S: Oxford–AstraZeneca. BNT162b2: Pfizer–BioNTech. PSI: Pneumonia Severity Index. NEWS-2: National Early Warning Score. Ferritin: Serum values expressed in ng/mL. Lymphocytes: Blood values expressed in cells per microliter of blood. PLR: Platelet-to-lymphocyte ratio.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap position="float" id="vaccines-12-00072-t008">
      <object-id pub-id-type="pii">vaccines-12-00072-t008_Table 8</object-id>
      <label>Table 8</label>
      <caption>
        <p>Cutoff scores, area under the curve (AUC), sensitivity, and specificity for various clinical measures examined in this study.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Group</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AUC</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">S.E.</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th>
            <th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">95% CI</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cutoff</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sens</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Spec</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">PSI</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Not vac</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.92</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.01</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.91</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.93</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">118.0</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.80</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.10</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">ChAdOx1-S</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.89</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.01</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.86</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.92</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">123.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.78</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.17</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.85</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.88</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">124.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.22</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Oxemia</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Not vac</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.35</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.02</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.31</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.39</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">74.0</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.92</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.95</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">ChAdOx1-S</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.35</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.04</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.26</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.43</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">84.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.83</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.93</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.41</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.34</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.47</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.83</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.86</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Lymphocytes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Not vac</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.39</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.02</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.36</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.42</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">535.0</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.44</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.59</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">ChAdOx1-S</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.32</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.03</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.27</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.37</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">831.4</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.37</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.67</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.38</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.34</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.43</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">893.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.40</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.57</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Neutrophils</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Not vac</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.69</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.01</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.67</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.72</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7311.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.62</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.30</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">ChAdOx1-S</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.62</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.03</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.57</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.68</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">9710.9</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.65</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.43</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.72</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.68</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.76</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9430.1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.70</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.37</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">LDH</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Not vac</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.75</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.02</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.72</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.78</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">367.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.62</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.25</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">ChAdOx1-S</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.87</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.03</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.82</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.92</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">332.7</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.79</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.17</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.76</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.70</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">325.4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.69</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.30</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Ferritin</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Not vac</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.64</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.02</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.60</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.67</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">875.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.59</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.41</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">ChAdOx1-S</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.57</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.04</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.090</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.49</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.64</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">878.4</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.53</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.46</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.67</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.61</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.73</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">648.3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.41</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">CRP</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Not vac</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.74</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.02</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.71</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.78</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">12.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.60</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.25</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">ChAdOx1-S</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.57</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.05</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.162</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.47</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.67</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">12.3</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.56</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.49</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.71</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.68</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.74</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.60</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.30</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">D dimer</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Not vac</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.74</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.02</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.70</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.77</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1009.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.64</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.31</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">ChAdOx1-S</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.71</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.04</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.64</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.79</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1231.7</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.62</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.48</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.69</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.62</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1083.0</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.63</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.40</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">eGFR</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Not vac</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.32</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.01</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.29</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.34</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">75.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.42</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.73</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">ChAdOx1-S</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.43</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.03</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.009</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.37</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.48</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">36.3</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.46</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.59</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.431</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.024</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.384</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.479</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.00</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.436</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.598</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>AUC: Area under the curve. S.E.: Standard error. CI: Confidence intervals. Sens: Sensitivity. Spec: Specificity. Not vac: Not vaccinated. ChAdOx1-S: Oxford–AstraZeneca. BNT162b2: Pfizer–BioNTech. PSI: Pneumonia Severity Index. Oxemia: Arterial oxemia (%). Lymphocytes and neutrophils expressed in cells per microliter of blood. LDH: Lactate Dehydrogenase expressed in international units per liter. Ferritin expressed in ng/mL. CRP: C-Reactive Protein mg/dL. D dimer expressed in ng/mL. eGFR: estimated glomerular filtration rate, expressed in mL/min/1.73 m<sup>2</sup>.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap position="float" id="vaccines-12-00072-t009">
      <object-id pub-id-type="pii">vaccines-12-00072-t009_Table 9</object-id>
      <label>Table 9</label>
      <caption>
        <p>Mean values of various clinical parameters throughout the entire hospitalization period categorized by vaccine type, along with <italic toggle="yes">p</italic>-values resulting from the analysis using multivariate linear mixed effects models.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
            <th colspan="3" align="center" valign="middle" style="border-top:solid thin" rowspan="1">Vaccine</th>
            <th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1"><italic toggle="yes">p</italic>-Value No vs.</th>
            <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">ChAdOx1-S<break/>vs.</th>
          </tr>
          <tr>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variable</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChAdOx1-S</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChAdOx1-S</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">PSI</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">119.1 ± 45.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">117.5 ± 41.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">128.1 ± 42.3</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.496</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Oxemia</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">90.68 ± 10.18</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">90.91 ± 9.95</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">90.78 ± 10.43</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.826</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.925</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.807</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">pH</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.339 ± 0.16</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.333 ± 0.15</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.360 ± 0.14</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.314</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.034</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.014</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Lymphocytes </td>
            <td align="center" valign="middle" rowspan="1" colspan="1">691.9 ± 722.0</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1040.4 ± 721.8</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1091.1 ± 856.6</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.102</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Neutrophils</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">8309.4 ± 6674.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">11,972.3 ± 7959.6</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">10,479.9 ± 5828.0</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.024</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">LDH</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">421.9 ± 400.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">416.3 ± 568.0</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">370.5 ± 258.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.814</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.046</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.166</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">ALP</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">92.4 ± 61.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">170.3 ± 162.8</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">106.1 ± 75.6</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.006</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.024</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">AST</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">56.4 ± 177.4</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">80.6 ± 224.9</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">62.0 ± 171.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.148</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.628</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.402</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">ALT</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">45.2 ± 58.6</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">63.6 ± 149.6</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">49.2 ± 121.7</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.002</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.389</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.520</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Ferritin</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1129.4 ± 769.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1130.3 ± 790.9</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">807.8 ± 616.3</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.673</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Platelets</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">257.5 ± 136.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">264.5 ± 155.6</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">270.1 ± 131.3</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.057</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.894</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.130</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">MPV</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">10.7 ± 1.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">10.5 ± 1.0</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">10.7 ± 1.2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.006</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.706</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.042</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">CRP</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">14.8 ± 19.9</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">14.1 ± 9.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">13.0 ± 17.7</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.699</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.230</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.562</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">D dimer</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2475.5 + 12,065.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3312.1 ± 4438.8</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2090.2 ± 2737.1</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.444</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.611</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.002</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">eGFR</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84.8 ± 66.2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62.8 ± 65.4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70.9 ± 53.8</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.004</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt; 0.001</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.826</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>No: not vaccinated. ChAdOx1-S: Oxford–AstraZeneca. BNT162b2: Pfizer–BioNTech. PSI: Pneumonia Severity Index. Oxemia: Arterial oxemia (%). Lymphocytes and neutrophils expressed in cells per microliter of blood. LDH: Lactate Dehydrogenase expressed in international units per liter (IU/L). ALP: alkaline phosphatase, expressed in IU/L. AST: aspartate amino transferase, expressed in IU/L. ALT: alanine aminotransferase, expressed in IU/L. Ferritin expressed in ng/mL. Platelets X1000, expressed in cells per microliter of blood. MPV: mean platelet volume expressed in femtoliter. CRP: C-Reactive Protein mg/dL. D dimer expressed in ng/mL. PLR: Platelet-to-lymphocyte ratio. eGFR: estimated glomerular filtration rate, expressed in mL/min/1.73 m<sup>2</sup>.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>
